EP4192495A1 - Fgf21 combined with ccr2/5 antagonists for the treatment of fibrosis - Google Patents

Fgf21 combined with ccr2/5 antagonists for the treatment of fibrosis

Info

Publication number
EP4192495A1
EP4192495A1 EP21773170.2A EP21773170A EP4192495A1 EP 4192495 A1 EP4192495 A1 EP 4192495A1 EP 21773170 A EP21773170 A EP 21773170A EP 4192495 A1 EP4192495 A1 EP 4192495A1
Authority
EP
European Patent Office
Prior art keywords
fgf
polypeptide
seq
ccr2
aspects
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP21773170.2A
Other languages
German (de)
English (en)
French (fr)
Inventor
Stephanie Lauren BOEHM
Qihong Zhao
Edgar Davidson Charles, Iii
Bradley A. Zinker
Frank TACKE
Tobias PUENGEL
Sander LEFERE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universiteit Gent
Universitaetsmedizin Berlin
Rheinisch Westlische Technische Hochschuke RWTH
Bristol Myers Squibb Co
Original Assignee
Universiteit Gent
Universitaetsmedizin Berlin
Rheinisch Westlische Technische Hochschuke RWTH
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universiteit Gent, Universitaetsmedizin Berlin, Rheinisch Westlische Technische Hochschuke RWTH, Bristol Myers Squibb Co filed Critical Universiteit Gent
Publication of EP4192495A1 publication Critical patent/EP4192495A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Definitions

  • This application pertains to, among other things, methods of treating or preventing a disease or condition related to fibrosis and/or diabetes, e.g., NASH by a combination therapy, including e.g., a FGF-21 polypeptide, e.g., a PEGylated FGF-21 polypeptide (PEG-FGF-21 conjugate), and a CCR2/5 dual antagonist, e.g., Compound A or Compound C.
  • a FGF-21 polypeptide e.g., a PEGylated FGF-21 polypeptide (PEG-FGF-21 conjugate)
  • PEG-FGF-21 conjugate PEGylated FGF-21 polypeptide
  • CCR2/5 dual antagonist e.g., Compound A or Compound C.
  • NASH Non-Alcoholic SteatoHepatitis. It can be defined as the liver manifestation of a metabolic disorder, and is the most severe form of non-alcoholic fatty liver disease (NAFLD). NASH is closely related to the triple epidemic of obesity, pre-diabetes, and diabetes. But its symptoms are often silent or non-specific to NASH, making it difficult to diagnose. As a result, NASH patients can remain unaware of their condition until late stages of the disease.
  • NASH can progress to more serious disease stages, such as advanced fibrosis, cirrhosis, liver failure, or liver cancer, driven by hepatocellular ballooning and inflammation.
  • liver transplant may be a patient’s only option. But this risky surgical procedure is associated with various complications, not to mention long waiting lists due to the lack of available healthy organs from donors, or eligibility issues related to patient condition. Therefore, there exists a need for an effective treatment for NASH.
  • the present disclosure is directed to a method of treating or preventing a disease or condition associated with fibrosis and/or diabetes in a subject in need thereof comprising administering to the subject an effective amount of a fibroblast growth factor 21 (FGF-21) polypeptide in combination with a CCR2/5 dual antagonist.
  • FGF-21 fibroblast growth factor 21
  • the FGF-21 polypeptide is administered sequentially with the CCR2/5 dual antagonist, in any order.
  • the FGF-21 polypeptide is administered concurrently with the CCR2/5 dual antagonist.
  • the disease or condition is diabetes, e.g., Type 2 diabetes.
  • the disease or condition is nonalcoholic steatohepatitis (NASH) or nonalcoholic fatty liver disease (NAFLD).
  • NASH nonalcoholic steatohepatitis
  • NAFLD nonalcoholic fatty liver disease
  • the administration of the FGF-21 polypeptide and the CCR2/5 dual antagonist to the subject decreases liver stiffness, decreases percentage body fat, decreases body weight, decreases liver-to-body weight ratio, decreases liver lipid content, decreases liver fibrosis area, decreases fasting blood glucose levels, decreases fasting triglyceride levels, decreases LDL cholesterol levels, decreases ApoB levels, decreases ApoC levels, increases HDL cholesterol, or any combination thereof.
  • the administration of the FGF-21 polypeptide in combination with the CCR2/5 dual antagonist to the subject results in (i) reduction in levels of liver fat; (ii) reduction in levels of liver injury; (iii) reduction in levels of fibrosis; (iv) decrease in levels of fibrosis biomarker serum Pro-C3 (N-terminal type III collagen propeptide); (v) decrease in levels of alanine aminotransferase (ALT); (vi) decrease in levels of aspartate aminotransferase (AST), (vii) increase in levels of serum adiponectin; (viii) decrease in levels of plasma LDL; (ix) increase in levels of plasma HDL; (x) decrease in levels of plasma triglyceride; (xi) reduction in level of liver stiffness; or (xii) any combination thereof, compared to the levels in untreated subjects or subjects prior to the administration of the pharmaceutical formulation, or to the levels in subjects treated only with the FGF-21 polypeptide or the CCR2
  • the administration of the FGF-21 polypeptide in combination with the CCR2/5 dual antagonist to the subject results in (a) reduction in numbers of hepatic monocytes; (b) reduction in numbers of F4/80-positive hepatic monocyte-derived macrophages (MoMF); or (c) both (a) and (b).
  • the FGF-21 polypeptide is linked or conjugated to a half-life extending moiety.
  • the half-life extending moiety comprises a polypeptide moiety.
  • the half-life extending moiety comprises an Fc region, albumin, a PAS sequence, transferrin or CTP (28 amino acid C-terminal peptide (CTP) of hCG with its 4 O- glycans), an albumin binding polypeptide, an albumin-binding small molecule, or any combinations thereof.
  • the half-life extending moiety comprises a nonpolypeptide moiety.
  • the half-life extending moiety comprises polyethylene glycol (PEG), hydroxyethyl starch (HES), polysialic acid, or any combination thereof.
  • the FGF-21 polypeptide is conjugated to a polyethylene glycol (PEG) moiety (“FGF-21 conjugate”).
  • FGF-21 conjugate comprises:
  • the PEG moiety is conjugated to a non-natural amino acid in the FGF-21 polypeptide.
  • the non-natural amino acid in the FGF-21 polypeptide is a phenylalanine derivative.
  • the phenylalanine derivative is para-acetyl-L- phenylalanine.
  • the FGF-21 polypeptide comprises an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% amino acid sequence identity to the amino acid sequence of SEQ ID NO: 3, 7, 11, or 15, wherein the polypeptide has a FGF-21 activity.
  • the FGF-21 polypeptide has a deletion, insertion, and/or substitution.
  • the non-natural amino acid is at amino acid residue 109 corresponding to SEQ ID NO: 3 or 11.
  • the FGF-21 polypeptide comprises the sequence as set forth in SEQ ID NO: 1, 5, 9, or 13.
  • the FGF-21 conjugate corresponds to a compound of SEQ ID NO: 2, 6, 10, or 14.
  • the n is from about 500 to about 900 ethylene glycol units, from about 600 to about 800 ethylene glycol units, from about 650 to about 750 ethylene glycol units, or from about 670 to about 690. In some aspects, the n is between about 670 and about 690, e.g., about 681.
  • the FGF-21 polypeptide corresponds to a compound of SEQ ID NO: 4, 8, 12, or 16. In some aspects, the FGF-21 polypeptide comprises the sequence as set forth in SEQ ID NO: 4 or 12. In some aspects, the FGF-21 conjugate is in an L conformation.
  • the FGF-21 polypeptide is formulated with an aminopolycarboxylic acid cation chelator, a surfactant, an amino acid buffering agent, an osmotic regulator, or any combination thereof.
  • the CCR2/5 dual antagonist is a polypeptide. In some aspects, the CCR2/5 dual antagonist is a small molecule. In some aspects, the CCR2/5 dual antagonist is a compound of formula (X): or a pharmaceutically acceptable salt thereof, wherein:
  • R 1 is hydrogen or Ci-Ce alkyl
  • R 8 and R 9 are independently selected from hydrogen and Ci-Ce alkyl
  • R 10 is Ci-C 6 alkyl
  • Het is an optionally substituted 3- to 14-membered monocyclic or bicyclic heterocyclyl or heteroaryl ring having at least one nitrogen atom;
  • R a and R b are each hydrogen, or, together form an oxo group; and Z is NH or CH2.
  • the CCR2/5 dual antagonist is compound (A): In some aspects, the CCR2/5 dual antagonist is a pharmaceutically acceptable salt of compound
  • the CCR2/5 dual antagonist is compound (C):
  • the CCR2/5 dual antagonist is a pharmaceutically acceptable salt of compound (C).
  • the subject is human.
  • the method is treating the disease or condition associated with fibrosis and/or diabetes.
  • the present disclosure provides a method of treating NASH in a human subject in need thereof comprising administering to the human subject an effective amount of (1) the PEG-FGF-21 conjugate of Formula I
  • Modified FGF-21 (Formula I), wherein an about 30 kD PEG moiety with n being between about 670 and about 690 is conjugated to the para-acetyl-L-phenylalanine of the FGF-21 polypeptide of SEQ ID NO: 2 or 10; in combination with (2) compound C (compound C).
  • FGF-21 conjugate of Formula I is combined with a pharmaceutically acceptable salt of Compound C.
  • the PEG moiety comprises a distal methoxy (-O-CH3) group.
  • n is about 681.
  • the CCR2/5 dual antagonist useful for the method is compound
  • the CCR2/5 dual antagonist useful for the method is a pharmaceutically acceptable salt of Compound C:
  • FIGS. 1A and IB show CCL2 and FGF-21 serum levels measured by ELISA and correlated with histologically assessed severity of liver fibrosis and steatohepatitis.
  • FIGS. 1A and IB show CCL2 and FGF-21 serum levels measured by ELISA and correlated with histologically assessed severity of liver fibrosis and steatohepatitis.
  • FIGS. 1A and IB show CCL2 and FGF-21 serum levels measured by ELISA and correlated with histologically assessed severity of liver fibrosis and
  • FIG. IE shows association of FGF-21 serum levels with biomarkers of steatohepatitis (CK-18 M30, GGT and AST).
  • FIG. 2A shows that acute liver injury was induced by a single CCh injection. Mice received vehicle (Vhc), CCR2/CCR5 inhibitor (CCR2/5i) and/or PEG-FGF21 variant (FGF21v).
  • FIGS. 2C and 2D show quantification of F4/80 positive area fraction.
  • FIGS. 3A-3J shows combination therapy by dual CCR2/CCR5 inhibition and FGF21 agonism ameliorates steatohepatitis and fibrosis more effectively than single drug treatment.
  • FIG. 3A shows pharmacologic treatment with CCR2/CCR5 inhibitor (CCR2/5i) and/or PEG-FGF21 variant (FGF21v) was conducted over the last 6 weeks of 12 weeks CDAHFD (choline-deficient, amino acid-defined high-fat diet) administration to induce steatohepatitis and fibrosis.
  • FIG. 3B shows a line graph of bodyweight development of all treatment groups (ctrl: control diet; Vhc: vehicle).
  • FIGS. 3D-3F present an assessment of liver injury by serum alanine transaminase levels (ALT), of liver fibrosis by quantification of Sirius Red area fraction and hydroxyproline content and of hepatic triglyceride content.
  • FIG. 3G shows single parameters of the histopathological NAFLD activity score (NAS).
  • FIGS. 4A-4F shows the beneficial effects of combination therapy after short term treatment.
  • FIG. 4 A shows that steatohepatitis and fibrosis were induced by CDAHFD (choline- deficient, amino acid-defined high-fat diet) over a total period of 8 weeks. Effects of pharmacologic treatment were assessed after administration of CCR2/CCR5 inhibitor (CCR2/5i) and/or PEG-FGF21 variant (FGF21v) over the last two weeks of injury induction.
  • FIGS. 4C and 4D show serum alanine transaminase (ALT) levels, NAFLD activity score, hepatic triglyceride and hydroxyproline content as well as quantification of Sirius Red area fraction display the liver phenotype.
  • FIGS. 5A-5F show the effects of combination treatment after long term treatment.
  • FIG. 5A shows that chronic liver injury was induced over a total period of 12 weeks and effects of pharmacologic treatment with vehicle (Vhc), CCR2/CCR5 inhibitor (CCR2/5i) and/or PEG- FGF21 variant (FGF21v) was assessed after administration over the last 6 weeks of 12 weeks injury induction.
  • FIG. 5E shows the quantification of serum CCL2, CCL5 and CXCL1 levels by ELISA.
  • FIGS. 6A and 6B show lymphocyte populations in long term chronic liver injury.
  • FIG. 6A shows the quantification of lymphocyte immune cell populations in blood (B cells, CD4+ T cells, CD8+ T cells, NK cells and NKT cells).
  • FIG. 6B shows the quantification of lymphocyte immune cell populations in liver (B cells, CD4+ T cells, CD8+ T cells, NK cells and NKT cells).
  • FIG. 7 shows schematic representations of PEGylated FGF-21 conjugates of the present disclosure.
  • the top drawing shows an FGF-21 conjugate in which the non-natural amino acid in the FGF-21 conjugate is para-acetyl-phenylalanine, e.g., para-acetyl-L-phenylalanine.
  • n represents the number of ethylene glycol units contained in the PEG polymer.
  • the bottom drawing is a schematic representation of a specific PEG linker comprising 681 ethylene glycol units that can be fused or conjugated in a site specific manner to a FGF-21 polypeptide (e.g., a FGF-21 polypeptide comprising a non-native amino acid such as para-acetyl-phenylalanine, e.g., para-acetyl-L-phenylalanine) to yield a FGF-21 conjugate of the present disclosure.
  • a FGF-21 polypeptide e.g., a FGF-21 polypeptide comprising a non-native amino acid such as para-acetyl-phenylalanine, e.g., para-acetyl-L-phenylalanine
  • the present disclosure provides a method of treating a subject afflicted with a fibrosis and/or diabetes comprising administering a fibroblast grow factor 21 (FGF-21) polypeptide, e.g., such as PEG-FGF-21 (e.g., SEQ ID NO: 2, 4, 6, 8, 10, 12, 14 or 16) in combination with a CCR2/5 dual antagonist.
  • FGF-21 fibroblast grow factor 21
  • PEG-FGF-21 e.g., SEQ ID NO: 2, 4, 6, 8, 10, 12, 14 or 16
  • the disclosure includes aspects in which exactly one member of the group is present in, employed in, or otherwise relevant to a given product or process.
  • the disclosure includes aspects in which more than one, or all of the group members are present in, employed in, or otherwise relevant to a given product or process.
  • amino acid substitution refers to replacing an amino acid residue present in a parent or reference sequence (e.g., a wild type sequence) with another amino acid residue.
  • An amino acid can be substituted in a parent or reference sequence (e.g., a wild type polypeptide sequence), for example, via chemical peptide synthesis or through recombinant methods known in the art. Accordingly, a reference to a "substitution at position X” refers to the substitution of an amino acid present at position X with an alternative amino acid residue.
  • substitution patterns can be described according to the schema AnY, wherein A is the single letter code corresponding to the amino acid naturally or originally present at position n, and Y is the substituting amino acid residue.
  • substitution patterns can be described according to the schema An(YZ), wherein A is the single letter code corresponding to the amino acid residue substituting the amino acid naturally or originally present at position n, and Y and Z are alternative substituting amino acid residues that can replace A.
  • substitutions are conducted at the nucleic acid level, i.e., substituting an amino acid residue with an alternative amino acid residue is conducted by substituting the codon encoding the first amino acid with a codon encoding the second amino acid.
  • the term “approximately,” as applied to one or more values of interest, refers to a value that is similar to a stated reference value. In certain aspects, the term “approximately” refers to a range of values that fall within 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, or less in either direction (greater than or less than) of the stated reference value unless otherwise stated or otherwise evident from the context (except where such number would exceed 100% of a possible value).
  • association means that the symptom, measurement, characteristic, or status in question is linked to the diagnosis, development, presence, or progression of that disease. As association may, but need not, be causatively linked to the disease.
  • biologically active as applied to a molecule disclosed herein, for example, a FGF-21 conjugate disclosed herein, e.g., a PEG-FGF-21 of SEQ ID NO: 2 or 10 or SEQ ID NO:4 or 12, means any substance which can affect any physical or biochemical properties of a biological system, pathway, molecule, or interaction relating to a living organism.
  • biologically active molecules include, but are not limited to, any substance intended for diagnosis, cure, mitigation, treatment, or prevention of disease or conditions, e.g., diseases or conditions associated with fibrosis, in humans or other animals, or to otherwise enhance physical or mental well-being of humans or animals.
  • CCR2/5 dual antagonist A "CCR2/5 dual antagonist” is an antagonist that binds potently to CCR2 and CCR5 receptors and exhibits potent dual inhibition of in vitro receptor-mediated functions such as CCR2- and CCR5-mediated functions such as calcium flux and chemotaxis in response to their respective cognate ligands.
  • Compounds having CCR2/5 dual inhibitory activity are reported in, for example, U.S. Pat. Nos. 8,383,812 and 7,163,937, which are incorporated by reference in their entireties.
  • alkyl refers to a group derived from a straight or branched chain saturated hydrocarbon.
  • heterocyclyl refers to substituted or unsubstituted nonaromatic (which may be partially or fully saturated) 3- to 14-membered rings having 1 to 4 heteroatoms. Such rings can be 3- to 7-membered monocyclic groups, 7- to 11-membered bicyclic groups, or 10- to 14-membered tricyclic groups.
  • Each ring of the heterocyclyl group containing a heteroatom can contain one or two oxygen or sulfur atoms and/or from 1 to 4 nitrogen atoms provided that the total number of heteroatoms in each ring is four or less, and further provided that the ring contains at least one carbon atom.
  • the fused rings completing bicyclic and tricyclic groups may contain only carbon atoms and may be saturated, partially saturated, or unsaturated.
  • the nitrogen and sulfur atoms may optionally be oxidized and the nitrogen atoms may optionally be quaternized.
  • the heterocyclyl group may be attached at any available nitrogen or carbon atom.
  • heterocyclic groups include, but are not limited to, azetidinyl pyrrolidinyl, oxetanyl, imidazolinyl, oxazolidinyl, isoxazolinyl, thiazolidinyl, isothiazolidinyl, tetrahydrofuranyl, piperidyl, piperazinyl, 2-oxopiperazinyl, 2-oxopiperidyl, 2-oxopyrrolodinyl, 2-oxoazepinyl, azepinyl, 4-piperidonyl, etrahydropyranyl, morpholinyl, thiamorpholinyl, thiamorpholinyl sulfoxide, thiamorpholinyl sulfone, 1,3 -di oxolane, quinuclidinyl, tetrahydro-1, 1 -di oxothienyl and the like.
  • heteroaryl refers to substituted and unsubstituted aromatic 3- to 14- membered rings having 1 to 4 heteroatoms selected from 0, S, or N in at least one of the rings.
  • Said rings can be 5- or 6-membered monocyclic groups, 9- to 14-membered bicyclic groups, or 11- to 14-membered tricyclic groups.
  • Each ring of the heteroaryl group containing a heteroatom can contain one or two oxygen or sulfur atoms and/or from 1 to 4 nitrogen atoms provided that the total number of heteroatoms in each ring is four or less and each ring has at least one carbon atom.
  • the fused rings completing the bicyclic and tricyclic groups may contain only carbon atoms and may be saturated, partially saturated, or unsaturated.
  • the nitrogen and sulfur atoms may optionally be oxidized and the nitrogen atoms may optionally be quatemized.
  • Heteroaryl groups which are bi cyclic or tricyclic must include at least one fully aromatic ring but the other fused ring or rings may be aromatic or non-aromatic.
  • the heteroaryl group may be attached at any available nitrogen or carbon atom of any ring.
  • heteroaryl groups include pyrrolyl, pyrazolyl, pyrazolinyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, thia-diazolyl, isothiazolyl, furanyl, thienyl, oxadiazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, triazinyl, indolyl, benzothiazolyl, benzodi oxolyl, benzoxazolyl, benzothienyl, quinolinyl, tetrahydroisoquinolinyl, isoquinolinyl, benzimidazolyl, benzopyranyl, indolizinyl, benzofuranyl, chromonyl, coumarinyl benzopyranyl, cinnolinyl, quinoxalinyl, indazolyl pyr
  • Conservative amino acid substitution is one in which the amino acid residue is replaced with an amino acid residue having a similar side chain.
  • Families of amino acid residues having similar side chains have been defined in the art, including basic side chains (e.g., lysine, arginine, or histidine), acidic side chains (e.g., aspartic acid or glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, or cysteine), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, or tryptophan), beta-branched side chains (e.g., threonine, valine, isoleucine) and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, or
  • amino acid substitution is considered to be conservative.
  • a string of amino acids can be conservatively replaced with a structurally similar string that differs in order and/or composition of side chain family members.
  • Non-conservative amino acid substitutions include those in which (i) a residue having an electropositive side chain (e.g, Arg, His or Lys) is substituted for, or by, an electronegative residue (e.g, Glu or Asp), (ii) a hydrophilic residue (e.g., Ser or Thr) is substituted for, or by, a hydrophobic residue (e.g., Ala, Leu, He, Phe or Vai), (iii) a cysteine or proline is substituted for, or by, any other residue, or (iv) a residue having a bulky hydrophobic or aromatic side chain (e.g., Vai, His, He or Trp) is substituted for, or by, one having a smaller side chain (e.g., Ala or Ser) or no side chain (e.g., Gly).
  • a residue having an electropositive side chain e.g, Arg, His or Lys
  • an electronegative residue e.g, Glu or As
  • amino acid substitutions can also be used.
  • a substitution can be taken from any one of D-alanine, glycine, beta-alanine, L-cysteine and D-cysteine.
  • a replacement can be any one of D-lysine, arginine, D-arginine, homo-arginine, methionine, D-methionine, ornithine, or D- ornithine.
  • substitutions in functionally important regions that can be expected to induce changes in the properties of isolated polypeptides are those in which (i) a polar residue, e.g., serine or threonine, is substituted for (or by) a hydrophobic residue, e.g., leucine, isoleucine, phenylalanine, or alanine; (ii) a cysteine residue is substituted for (or by) any other residue; (iii) a residue having an electropositive side chain, e.g., lysine, arginine or histidine, is substituted for (or by) a residue having an electronegative side chain, e.g., glutamic acid or aspartic acid; or (iv) a residue having a bulky side chain, e.g., phenylalanine, is substituted for (or by) one not having such a side chain, e.g., glycine.
  • a polar residue e.g
  • conserved refers to amino acid residues of a polypeptide sequence, respectively, that are those that occur unaltered in the same position of two or more sequences being compared. Amino acids that are relatively conserved are those that are conserved amongst more related sequences than nucleotides or amino acids appearing elsewhere in the sequences. [0057] In some aspects, two or more sequences are said to be “completely conserved” or “identical” if they are 100% identical to one another. In some aspects, two or more sequences are said to be "highly conserved” if they are at least 70% identical, at least 80% identical, at least 90% identical, or at least 95% identical to one another.
  • two or more sequences are said to be "highly conserved” if they are about 70% identical, about 80% identical, about 90% identical, about 95%, about 98%, or about 99% identical to one another. In some aspects, two or more sequences are said to be "conserved” if they are at least 30% identical, at least 40% identical, at least 50% identical, at least 60% identical, at least 70% identical, at least 80% identical, at least 90% identical, or at least 95% identical to one another.
  • two or more sequences are said to be "conserved” if they are about 30% identical, about 40% identical, about 50% identical, about 60% identical, about 70% identical, about 80% identical, about 90% identical, about 95% identical, about 98% identical, or about 99% identical to one another. Conservation of sequence may apply to the entire length of a polynucleotide or polypeptide or may apply to a portion, region or feature thereof.
  • Deamidation refers to the tendency of amino acid residues within a polypeptide to spontaneously undergo a deamidation reaction, thereby changing the chemical structure of the amino acid, and potentially affecting the function of the polypeptide. Exemplary methods of measuring deamidation are disclosed in the Examples herein. The relative amount of deamidation may be determined with respect to a reference compound, e.g., to identify a polypeptide having decreased deamidation.
  • Relative amounts of deamidation can also be determined with respect to a reference formulation, e.g., to identify a formulation in which a FGF-21 conjugate disclosed herein, e.g., a PEG-FGF-21 of SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, or 16, has reduced deamidation.
  • a FGF-21 conjugate disclosed herein e.g., a PEG-FGF-21 of SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, or 16 has reduced deamidation.
  • Disease associated with fibrosis includes diseases, disorders, and conditions in which fibrosis has been observed to occur or in which fibrosis is known or thought to be associated with or contribute to disease etiology, progression, or symptoms, or in which fibrosis is known or thought to occur as the disease progresses.
  • the fibrosis may affect an organ or tissue such as the pancreas, lung, heart, kidney, liver, eyes, nervous system, bone marrow, lymph nodes, endomyocardium, or retroperitoneum.
  • exemplary diseases associated with fibrosis include, but are not limited to nonalcoholic steatohepatitis (NASH), liver fibrosis, pre-cirrhosis, cirrhosis, diffuse parenchymal lung disease, cystic fibrosis, lung or pulmonary fibrosis, progressive massive fibrosis, idiopathic pulmonary fibrosis, injection fibrosis, kidney or renal fibrosis, chronic kidney disease, diabetic kidney disease, focal segmental glomerulosclerosis, membranous nephropathy, IgA nephropathy, myelofibrosis, heart failure, metabolic heart failure, cardiac fibrosis, cataract fibrosis, cataract, ocular scarring, pancreatic fibrosis, skin fibrosis, intestinal fibros
  • the disease associated with fibrosis can include liver fibrosis, kidney or renal fibrosis, lung or pulmonary fibrosis and heart or cardiac fibrosis. In some aspects, the disease associated with fibrosis can be liver fibrosis. In some aspects, the disease associated with fibrosis can be NASH.
  • Effective Amount As used herein, the term "effective amount" of a formulation comprising a FGF-21 polypeptide disclosed herein, e.g., a PEG-FGF-21 of SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, or 16, or a CCR2/5 dual antagonist is that amount sufficient to effect beneficial or desired results, for example, clinical results, and, as such, an "effective amount" depends upon the context in which it is being applied.
  • an effective amount of the FGF-21 polypeptide and CCR2/5 dual antagonist is, for example, an amount sufficient to improve liver fat, liver injury or fibrosis (e.g., a reduction in liver fat, liver injury or fibrosis with respect to levels in untreated subjects or with respect to levels in the subject prior to the administration of the treatment; or with respect to the subject prior to the administration of the FGF-21 polypeptide but after the administration of the CCR2/5 dual antagonist, or vice versa).
  • an effective amount of a FGF-21 polypeptide disclosed herein e.g., a PEG-FGF-21 of SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, or 16, and CCR2/5 dual antagonist to treat NASH can change the level of one or more fibrosis biomarkers: for example, decrease serum Pro-C3; decrease ALT or AST; increase serum adiponectin; decrease plasma LDL; increase plasma HDL; decrease plasma triglyceride levels, or any combination thereof, with respect to levels in untreated subjects or with respect to levels in the subject prior to the administration of the treatment.
  • fibrosis biomarkers for example, decrease serum Pro-C3; decrease ALT or AST; increase serum adiponectin; decrease plasma LDL; increase plasma HDL; decrease plasma triglyceride levels, or any combination thereof, with respect to levels in untreated subjects or with respect to levels in the subject prior to the administration of the treatment.
  • FGF-21 activity refers to at least one biological activity of a FGF-21 polypeptide or FGF-21 conjugate (e.g., a PEG-FGF-21 conjugate of the present disclosure).
  • biological activity refers to the ability of a molecule, e.g., an FGF-21 polypeptide (e.g., a FGF-21 polypeptide or a FGF-21 conjugate disclosed herein, e.g., a PEG-FGF-21 of SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, or 16) to affect any physical or biochemical properties of a biological system, pathway, molecule, or interaction relating to an organism, including but not limited to, viruses, bacteria, bacteriophage, transposon, prion, insects, fungi, plants, animals, and humans.
  • biological activity includes any of the biological functions performed by wild-type FGF-21.
  • Exemplary methods of determining whether a molecule possesses at least one biological activity of wild-type FGF-21 can include any functional assays known in the art, including the methods disclosed in Example 5 and 17 of U.S. Appl Publ. No. 2017/0189486, which is herein incorporated by reference in its entirety.
  • Identity refers to the overall monomer conservation between polymeric molecules, e.g., between polypeptide molecules.
  • Calculation of the percent identity of two polypeptide sequences can be performed by aligning the two sequences for optimal comparison purposes (e.g., gaps can be introduced in one or both of a first and a polypeptide sequences for optimal alignment and nonidentical sequences can be disregarded for comparison purposes).
  • the length of a sequence aligned for comparison purposes is at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or 100% of the length of the reference sequence.
  • the amino acids at corresponding amino acid positions are then compared.
  • Suitable software programs are available from various sources, and for alignment of both protein and nucleotide sequences.
  • One suitable program to determine percent sequence identity is bl2seq, part of the BLAST suite of program available from the U.S. government's National Center for Biotechnology Information BLAST web site (blast.ncbi.nlm.nih.gov).
  • B12seq performs a comparison between two sequences using either the BLASTN or BLASTP algorithm.
  • BLASTN is used to compare nucleic acid sequences
  • BLASTP is used to compare amino acid sequences.
  • Suitable programs are, e.g., Needle, Stretcher, Water, or Matcher, part of the EMBOSS suite of bioinformatics programs and also available from the European Bioinformatics Institute (EBI) at www.ebi.ac.uk/Tools/psa. Sequence alignments can be conducted using methods known in the art such as MAFFT, Clustal (ClustalW, Clustal X or Clustal Omega), MUSCLE, etc.
  • Different regions within a single polypeptide target sequence that aligns with a polypeptide reference sequence can each have their own percent sequence identity. It is noted that the percent sequence identity value is rounded to the nearest tenth. For example, 80.11, 80.12, 80.13, and 80.14 are rounded down to 80.1, while 80.15, 80.16, 80.17, 80.18, and 80.19 are rounded up to 80.2. It also is noted that the length value will always be an integer.
  • a sequence alignment for the calculation of a percent sequence identity is not limited to binary sequence-sequence comparisons exclusively driven by primary sequence data.
  • sequence alignments can be generated by integrating sequence data with data from heterogeneous sources such as structural data (e.g., crystallographic protein structures), functional data (e.g., location of mutations), or phylogenetic data.
  • a suitable program that integrates heterogeneous data to generate a multiple sequence alignment is T-Coffee, available at www.tcoffee.org, and alternatively available, e.g., from the EBI. It will also be appreciated that the final alignment used to calculate percent sequence identity can be curated either automatically or manually.
  • in vivo proteolytic degradation refers to the cleavage of a polypeptide when introduced into a living system (e.g., when injected into an organism) which may result from proteases occurring in said organism. Proteolysis can potentially affect the biological activity or half-life of a polypeptide. For example, wild-type FGF-21 can undergo cleavage at the C-terminus, resulting in a truncated, inactive polypeptide.
  • An exemplary method of measuring in vivo proteolysis of FGF-21 is the Meso Scale Discovery (MSD)-based electrochemiluminescent immunosorbent assay (ECLIA) described in Example 10 of U.S. Appl. Publ. No. US2017/0189486.
  • MSD Meso Scale Discovery
  • ELIA electrochemiluminescent immunosorbent assay
  • the relative amount of in vivo proteolysis can also be determined with respect to a reference formulation, i.e., to identify a formulation in which the FGF-21 polypeptide moiety of a FGF-21 conjugate disclosed herein, e.g., a PEG-FGF-21 of SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, or 16, has decreased in vitro proteolysis.
  • a reference formulation i.e., to identify a formulation in which the FGF-21 polypeptide moiety of a FGF-21 conjugate disclosed herein, e.g., a PEG-FGF-21 of SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, or 16, has decreased in vitro proteolysis.
  • Isolated refers to a substance or entity (e.g., a polypeptide) that has been separated from at least some of the components with which it was associated (whether in nature or in an experimental setting). Isolated substances (e.g., proteins) can have varying levels of purity in reference to the substances from which they have been associated.
  • linked refers to a half-life extending moiety, e.g., a PEG moiety (e.g., a ⁇ 30 kD PEG moiety) covalently fused or concatenated, including internally inserted, to an FGF-21 polypeptide, e.g., a variant FGF-21 polypeptide disclosed herein (e.g., a FGF-21 polypeptide of SEQ ID NO: 1, 5,9, or 13).
  • a PEG moiety e.g., a ⁇ 30 kD PEG moiety
  • FGF-21 polypeptide e.g., a variant FGF-21 polypeptide disclosed herein (e.g., a FGF-21 polypeptide of SEQ ID NO: 1, 5,9, or 13).
  • a FGF-21 polypeptide e.g., a variant FGF-21 polypeptide disclosed herein (e.g., a FGF-21 polypeptide of SEQ ID NO: 1 , 5, 9, or 13), and a PEG moiety can be "fused" as a result of chemical synthesis.
  • conjugate or “conjugation” denote that two molecular entities (e.g., a FGF-21 polypeptide, e.g., a variant FGF-21 polypeptide disclosed herein and a polymer moiety such as PEG) have been chemically linked.
  • the FGF-21 polypeptide and the PEG moiety are linked via an oxime linkage as shown, for example, in formula I disclosed herein.
  • the PEG moiety comprises a distal methoxy (-O-CEE) group.
  • Non-natural amino acid refers to an amino acid that is not one of the 20 common amino acids or pyrrolysine or selenocysteine.
  • Other terms that can be used synonymously with the term “non-natural amino acid” are "non-naturally encoded amino acid,” “unnatural amino acid,” “non-naturally occurring amino acid,” and various hyphenated and non-hyphenated versions thereof.
  • non-natural amino acid also includes, but is not limited to, amino acids that occur by modification (e.g., post-translational modifications) of a naturally encoded amino acid (including but not limited to, the 20 common amino acids) but are not themselves naturally incorporated into a growing polypeptide chain by the translation complex.
  • non-natural amino acids include, but are not limited to, N-acetylglucosaminyl-L-serine, N- acetylglucosaminyl-L-threonine, and O-phosphotyrosine.
  • a non-natural amino acid is para-acetyl-phenylalanine.
  • a non-natural amino acid is para-acetyl-L-phenylalanine. In one specific aspect of the present disclosure, a non-natural amino acid is para-acetyl-D-phenylalanine.
  • composition refers to a preparation which is in such form as to permit the biological activity of the active ingredient (e.g., a FGF-21 polypeptide disclosed herein, e.g., a PEG-FGF-21 of SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, or 16) to be effective, and which contains no additional components (e.g., excipients and water) which are unacceptably toxic to a subject to which the composition would be administered.
  • the active ingredient e.g., a FGF-21 polypeptide disclosed herein, e.g., a PEG-FGF-21 of SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, or 16
  • Such composition can be sterile.
  • compositions, and/or dosage forms are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
  • approval by a regulatory agency of the Federal or state governments (or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia) for use in animals, and more particularly in humans implies that those compounds, materials, compositions, and/or dosage forms are pharmaceutically acceptable.
  • Compounds, materials, compositions, and/or dosage forms that are generally acceptable as safe for therapeutically purposes are "therapeutically acceptable.”
  • compositions comprising any ingredient other than the active compounds described herein (for example, a vehicle capable of suspending or dissolving the active compound) and having the properties of being substantially nontoxic and non-inflammatory in a subject.
  • Excipients can include, for example chelators, surfactants, buffering agents, osmotic regulators, antioxidants, emulsifiers, fillers (diluents), preservatives, sorbents, suspensing or dispersing agents, sweeteners, and waters of hydration. Excipients that are generally accepted as safe for therapeutic purposes are "therapeutically acceptable excipients.”
  • compositions described herein also includes pharmaceutically acceptable salts of the compounds described herein.
  • pharmaceutically acceptable salts refers to derivatives of the disclosed compounds wherein the parent compound is modified by converting an existing acid or base moiety to its salt form (e.g., by reacting the free base group with a suitable organic acid).
  • examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like.
  • Polypeptide' The terms “polypeptide,” “peptide,” and “protein” are used interchangeably herein to refer to polymers of amino acids of any length.
  • the polymer can comprise modified amino acids.
  • the terms also encompass an amino acid polymer that has been modified naturally or by intervention; for example, disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or any other manipulation or modification, such as conjugation with a labeling component.
  • polypeptides containing one or more analogs of an amino acid including, for example, unnatural amino acids such as homocysteine, ornithine, p-acetylphenylalanine, D-amino acids, and creatine
  • a polypeptide disclosed herein is a FGF-21 polypeptide.
  • polypeptides refers to proteins, polypeptides, and peptides of any size, structure, or function.
  • Polypeptides include gene products, naturally occurring polypeptides, synthetic polypeptides, homologs, orthologs, paralogs, fragments and other equivalents, variants, and analogs of the foregoing.
  • a polypeptide can be a single polypeptide or can be a multi- molecular complex such as a dimer, trimer or tetramer. They can also comprise single chain or multichain polypeptides. Most commonly disulfide linkages are found in multichain polypeptides.
  • polypeptide can also apply to amino acid polymers in which one or more amino acid residues are an artificial chemical analogue of a corresponding naturally occurring amino acid.
  • a "peptide" can be less than or equal to 50 amino acids long, e.g., about 5, 10, 15, 20, 25, 30, 35, 40, 45, or 50 amino acids long.
  • the term "preventing” refers to partially or completely delaying onset of an disease, disorder and/or condition; partially or completely delaying onset of one or more symptoms, features, or clinical manifestations of a particular disease, disorder, and/or condition; partially or completely delaying onset of one or more symptoms, features, or manifestations of a particular disease, disorder, and/or condition; partially or completely delaying progression from a particular disease, disorder and/or condition; and/or decreasing the risk of developing pathology associated with the disease, disorder, and/or condition.
  • the pharmaceutical formulation disclosed in the present application can be used to prevent the onset, prevent the symptoms, or prevent complications of diseases or conditions associated with fibrosis such as NASH or diabetes.
  • prophylactic refers to a therapeutic or course of action used to prevent the onset of a disease or condition, or to prevent or delay a symptom of a disease or condition associated with fibrosis, e.g., NASH.
  • pharmaceutical formulations disclosed in the present application can be used prophylactically.
  • Prophylaxis refers to a measure taken to maintain health and prevent or delay the onset of a disease or condition associates with fibrosis, e.g., NASH or diabetes, or to prevent or delay symptoms associated with a disease or condition.
  • a "recombinant" polypeptide or protein refers to a polypeptide or protein produced via recombinant DNA technology. Recombinantly produced polypeptides and proteins expressed in engineered host cells are considered isolated for the purpose of the disclosure, as are native or recombinant polypeptides which have been separated, fractionated, or partially or substantially purified by any suitable technique.
  • the variant FGF-21s disclosed herein can be recombinantly produced using methods known in the art.
  • the proteins and peptides disclosed herein can also be chemically synthesized.
  • a FGF-21 polypeptide useful for the disclosure e.g., a FGF-21 polypeptide comprising a non-natural amino acid, e.g., an FGF-21 of SEQ ID NO: 1, 5, 9, or 13
  • a bacterial host e.g., a bacterial host, a bacterial host, or a bacterial host, or a bacterial host, or a bacterial host.
  • Similarity refers to the overall relatedness between polymeric molecules, e.g. between polypeptide molecules. Calculation of percent similarity of polymeric molecules to one another can be performed in the same manner as a calculation of percent identity, except that calculation of percent similarity takes into account conservative substitutions as is understood in the art.
  • Subject' By “subject” or “individual” or “animal” or “mammal,” is meant any subject, particularly a mammalian subject, for whom diagnosis, prognosis, or therapy is desired. Mammalian subjects include, but are not limited to, humans, domestic animals, farm animals, zoo animals, sport animals, pet animals such as dogs, cats, guinea pigs, rabbits, rats, mice, horses, cattle, cows; primates such as apes, monkeys, orangutans, and chimpanzees; canids such as dogs and wolves; felids such as cats, lions, and tigers; equids such as horses, donkeys, and zebras; bears, food animals such as cows, pigs, and sheep; ungulates such as deer and giraffes; rodents such as mice, rats, hamsters and guinea pigs; and so on.
  • Mammalian subjects include, but are not limited
  • the mammal is a human subject.
  • a subject is a human patient.
  • a subject is a human patient or cells thereof whether in vivo, in vitro or ex vivo, amenable to the methods described herein.
  • Suffering from' An individual who is "suffering from" a disease, disorder, and/or condition has been diagnosed with or displays one or more symptoms of the disease, disorder, and/or condition.
  • the pharmaceutical formulations disclosed herein can be administered to a subject suffering from a disease or condition associated with fibrosis such as NASH or diabetes.
  • Susceptible to An individual who is "susceptible to" a disease, disorder, and/or condition has not been diagnosed with and/or may not exhibit symptoms of the disease, disorder, and/or condition but harbors a propensity to develop a disease or its symptoms.
  • an individual who is susceptible to a disease, disorder, and/or condition can be characterized by one or more of the following: (1) a genetic mutation associated with development of the disease, disorder, and/or condition; (2) a genetic polymorphism associated with development of the disease, disorder, and/or condition; (3) increased and/or decreased expression and/or activity of a protein and/or nucleic acid associated with the disease, disorder, and/or condition; (4) habits and/or lifestyles associated with development of the disease, disorder, and/or condition; (5) a family history of the disease, disorder, and/or condition; and (6) exposure to and/or infection with a microbe associated with development of the disease, disorder, and/or condition.
  • an individual who is susceptible to a disease, disorder, and/or condition will develop the disease, disorder, and/or condition. In some aspects, an individual who is susceptible to a disease, disorder, and/or condition will not develop the disease, disorder, and/or condition.
  • the pharmaceutical formulations disclosed herein can be administered to a subject susceptible to a disease or condition associated with fibrosis such as NASH or diabetes.
  • therapeutic agent refers to a molecular entity that, when administered to a subject, has a therapeutic, diagnostic, and/or prophylactic effect and/or elicits a desired biological and/or pharmacological effect.
  • a FGF-21 polypeptide disclosed herein e.g., a PEG-FGF-21 of SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, or 16
  • an agent is another molecule which is co-administered as part of a combination therapy with at least one FGF-21 conjugate disclosed herein, e.g., a PEG-FGF-21 of SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, or 16.
  • Therapeutically effective outcome means an outcome that is sufficient in a subject suffering from or susceptible to an infection, disease, disorder, and/or condition, to treat, improve symptoms of, diagnose, prevent, and/or delay the onset of the infection, disease, disorder, and/or condition.
  • the terms “treat” or “treatment” or “therapy” or grammatical variants thereof refer to partially or completely, preventing, alleviating, ameliorating, improving, relieving, delaying onset of, inhibiting progression of, reducing severity of, and/or reducing incidence of one or more symptoms or features of a disease or condition associated with fibrosis, e.g., NASH or diabetes.
  • “treating" a disease associated with fibrosis can refer to preventing symptoms, ameliorating symptoms, delaying the onset of the disease or condition or its symptoms, etc.
  • Treatment can be administered to a subject who does not exhibit signs of a disease, disorder, and/or condition and/or to a subject who exhibits only early signs of a disease, disorder, and/or condition for the purpose of decreasing the risk of developing pathology associated with the disease, disorder, and/or condition.
  • ug, uM, uL As used herein, the terms “ug,” “uM,” and “uL” are used interchangeably with “pg,” “pM,” and “pL” respectively.
  • the present disclosure also provides methods of treating or preventing a disease or condition associated with fibrosis and/or diabetes in a subject in need thereof comprising administering to the subject a FGF-21 polypeptide disclosed herein, e.g., a PEG-FGF-21 of SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, or 16, in combination with a CCR2/5 dual antagonist.
  • a FGF-21 polypeptide disclosed herein e.g., a PEG-FGF-21 of SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, or 16, in combination with a CCR2/5 dual antagonist.
  • the subject is administered an FGF-21 polypeptide disclosed herein concurrently with a CCR2/5 dual antagonist.
  • the subject is administered an FGF-21 polypeptide disclosed herein sequentially with a CCR2/5 dual antagonist.
  • the subject is administered the FGF-21 polypeptide disclosed herein prior to the CCR2/5 dual antagonist.
  • the subject is administered the FGF-21 polypeptide disclosed herein after the CCR2/5 dual antagonist.
  • the disease or condition is diabetes, e.g., type 2 diabetes.
  • the disease or condition is nonalcoholic steatohepatitis (NASH).
  • the disease or condition is nonalcoholic fatty acid disease (NAFAD).
  • the FGF-21 polypeptide and the CCR2/5 dual antagonist are administered subcutaneously, e.g., using a safety syringe or an auto-injector.
  • administration of the FGF-21 polypeptide and the CCR2/5 dual antagonist to the subject decreases liver stiffness, decreases percentage body fat, decreases body weight, decreases liver-to-body weight ratio, decreases liver lipid content, decreases liver fibrosis area, decreases fasting blood glucose levels, decreases fasting triglyceride levels, decreases LDL cholesterol levels, decreases ApoB levels, decreases ApoC levels, increases HDL cholesterol, or any combination thereof.
  • the administration of the FGF-21 polypeptide disclosed herein, e.g., a PEG-FGF-21 of SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, or 16, and the CCR2/5 dual antagonist, e.g., Compound A or Compound C, according to the methods of treatment disclosed herein to the subject results in (i) reduction in levels of liver fat; (ii) reduction in levels of liver injury; (iii) reduction in levels of fibrosis; (iv) decrease in levels of fibrosis biomarker serum Pro-C3 (N- terminal type III collagen propeptide); (v) decrease in levels of alanine aminotransferase (ALT); (vi) decrease in levels of aspartate aminotransferase (AST); (vii) increase in levels of serum adiponectin; (viii) decrease in levels of plasma LDL; (ix) increase in levels of plasma HDL; (x) decrease in levels of plasma triglyceride; (xi) reduction in level of liver
  • the administration of the FGF-21 polypeptide, e.g., a PEG-FGF- 21 of SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, or 16, and the CCR2/5 dual antagonist, e.g., Compound A or Compound C, according to the methods of treatment disclosed herein to the subject results in (i) reduction in levels of liver fat; (ii) reduction in levels of liver injury; (iii) reduction in levels of fibrosis; (iv) decrease in levels of fibrosis biomarker serum Pro-C3 (N-terminal type III collagen propeptide); (v) decrease in levels of alanine aminotransferase (ALT); (vi) decrease in levels of aspartate aminotransferase (AST), (vii) increase in levels of serum adiponectin; (viii) decrease in levels of plasma LDL; (ix) increase in levels of plasma HDL; (x) decrease in levels of plasma triglyceride; (xi) reduction in level of liver stiff
  • the administration of the FGF-21 polypeptide, e.g., a PEG-FGF- 21 of SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, or 16, in combination with the CCR2/5 dual antagonist, e.g., Compound A or Compound C, to the subject results in (a) reduction in numbers of hepatic monocytes; (b) reduction in numbers of F4/80-positive hepatic monocyte-derived macrophages (MoMF) or (c) both (a) and (b) compared to the levels in untreated subjects or to the subject prior to the administration of the FGF-21 polypeptide and/or the CCR2/5 dual antagonist.
  • the CCR2/5 dual antagonist e.g., Compound A or Compound C
  • the administration of the FGF-21 polypeptide, e.g., a PEG-FGF- 21 of SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, or 16, in combination with the CCR2/5 dual antagonist, e.g., Compound A or Compound C, to the subject results in (a) reduction in numbers of hepatic monocytes; (b) reduction in numbers of F4/80-positive hepatic monocyte-derived macrophages (MoMF) or (c) both (a) and (b) compared to the levels in subjects treated only with the FGF-21 polypeptide or the CCR2/5 dual antagonist, but not both.
  • the CCR2/5 dual antagonist e.g., Compound A or Compound C
  • the disease associated with fibrosis may affect an organ or tissue such as the pancreas, lung, heart, kidney, liver, eyes, nervous system, bone marrow, lymph nodes, endomyocardium, and/or retroperitoneum.
  • the disease associated with fibrosis may be liver fibrosis or pre-cirrhosis.
  • the disease associated with fibrosis may be selected from: nonalcoholic steatohepatitis (NASH), cirrhosis, diffuse parenchymal lung disease, cystic fibrosis, pulmonary fibrosis, progressive massive fibrosis, idiopathic pulmonary fibrosis, injection fibrosis, renal fibrosis, chronic kidney disease, diabetic kidney disease, focal segmental glomerulosclerosis, membranous nephropathy, IgA nephropathy, myelofibrosis, heart failure, acute heart failure, chronic heart failure, metabolic heart failure, cardiac fibrosis, cataract fibrosis, cataract, ocular scarring, pancreatic fibrosis, skin fibrosis, intestinal fibrosis, intestinal strictures, endomyocardial fibrosis, atrial fibrosis, mediastinal fibrosis, Crohn's disease, retroperitoneal fibrosis, keloid, nephrogenic systemic fibrosis, s
  • the disease associated with fibrosis results from one or more of pulmonary disease, lung cancer, drug therapy, chemotherapy, or radiation therapy. In some aspects, the disease associated with fibrosis results from one or more of aging, heart attack, stroke, myocardial damage, or left ventricular dysfunction. In some aspects, the disease associated with fibrosis may be selected from renal fibrosis, glomerular nephritis, chronic kidney disease, chronic kidney failure, and nephritis associated with systemic lupus, cancer, physical obstructions, toxins, metabolic disease, immunological diseases, or diabetic nephropathy.
  • the disease associated with fibrosis results from one or more of trauma, spinal injury, infection, surgery, ischemic injury, heart attack, burns, environmental pollutant exposure, pneumonia, tuberculosis, or acute respiratory distress syndrome.
  • the disease associated with fibrosis may be selected from pulmonary fibrosis, interstitial lung disease, human fibrotic lung disease, idiopathic pulmonary fibrosis, liver fibrosis, cardiac fibrosis, myocardial fibrosis, macular degeneration, retinal retinopathy, vitreal retinopathy, Grave's ophthalmopathy, drug induced ergotism, cardiovascular disease, atherosclerosis/restenosis, keloids and hypertrophic scars, primary or idiopathic myelofibrosis, inflammatory bowel disease, collagenous colitis, ocular scarring and cataract fibrosis.
  • the disease associated with fibrosis may be selected from NASH, liver fibrosis, and cirrhosis. In some aspects, the disease associated with fibrosis may be NASH. In some aspects, the disease associated with fibrosis may be selected from diabetic kidney disease, chronic kidney disease, and renal fibrosis. In some aspects, the disease associated with fibrosis may be selected from metabolic heart failure and cardiac fibrosis. In some aspects, the disease associated with fibrosis may be lung fibrosis.
  • the present disclosure provides a method of decreasing the hepatic fat fraction in a subject in need thereof, comprising administering to the subject a FGF-21 polypeptide disclosed herein, e.g., a PEG-FGF-21 of SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, or 16, and the CCR2/5 dual antagonist, e.g., Compound A or Compound C, wherein optionally the subject is at risk of developing or has been diagnosed with NASH.
  • a FGF-21 polypeptide disclosed herein e.g., a PEG-FGF-21 of SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, or 16, and the CCR2/5 dual antagonist, e.g., Compound A or Compound C, wherein optionally the subject is at risk of developing or has been diagnosed with NASH.
  • the present disclosure provides a method of decreasing liver stiffness, decreasing percentage body fat, decreasing body weight, decreasing liver-to-body weight ratio, decreasing liver lipid content, decreasing liver fibrosis area, decreasing fasting blood glucose levels, fasting triglyceride, decreasing LDL cholesterol, decreasing ApoB, decreasing ApoC, and/or increasing HDL cholesterol in a subject in need thereof, comprising administering to the subject an effective amount of a pharmaceutical formulation comprising a FGF-21 polypeptide disclosed herein, e.g., a PEG-FGF-21 of SEQ ID NO: 2, 4, 6, 8, 10, 12, 14 or 16, and the CCR2/5 dual antagonist, e.g., Compound A or Compound C, wherein optionally the subject is at risk of developing or has been diagnosed with NASH.
  • a pharmaceutical formulation comprising a FGF-21 polypeptide disclosed herein, e.g., a PEG-FGF-21 of SEQ ID NO: 2, 4, 6, 8, 10, 12, 14 or 16, and the CCR2/5 dual antagonist, e.g.
  • FGF-21 polypeptide disclosed herein e.g., a PEG-FGF-21 of SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, or 16, and the CCR2/5 dual antagonist, e.g., Compound A or Compound C, may here and in all other instances described herein also be administered as separate pharmaceutical formulations.
  • the present disclosure provides a method of increasing adiponectin levels in a subject in need thereof, comprising administering to the subject an effective amount of a pharmaceutical formulation comprising a FGF-21 polypeptide disclosed herein, e.g., a PEG-FGF-21 of SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, or 16, and the CCR2/5 dual antagonist, e.g., Compound A or Compound C, wherein optionally said subject is at risk of developing or has been diagnosed with NASH.
  • a pharmaceutical formulation comprising a FGF-21 polypeptide disclosed herein, e.g., a PEG-FGF-21 of SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, or 16, and the CCR2/5 dual antagonist, e.g., Compound A or Compound C, wherein optionally said subject is at risk of developing or has been diagnosed with NASH.
  • the present disclosure provides a method of treating one or more symptoms associated with NASH in a subject in need thereof, comprising administering to the subject an effective amount of a pharmaceutical formulation comprising a FGF-21 polypeptide disclosed herein, e.g., a PEG-FGF-21 of SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, or 16, and the CCR2/5 dual antagonist, e.g., Compound A or Compound C.
  • a pharmaceutical formulation comprising a FGF-21 polypeptide disclosed herein, e.g., a PEG-FGF-21 of SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, or 16, and the CCR2/5 dual antagonist, e.g., Compound A or Compound C.
  • a pharmaceutical formulation disclosed herein comprising a variant FGF-21 polypeptide comprising SEQ ID NO: 1, 5, 9 or 13, wherein the non-natural p-acetyl-phenylalanine residue thereof is linked via an oxime linkage to a PEG moiety with a molecular weight of about 28kDa to about 32 kDa.
  • the non-natural p-acetyl-phenylalanine substitutes glutamine 109 of wild type FGF-21 (SEQ ID NO: 3 or SEQ ID NO: 11).
  • the non-natural p- acetyl-phenylalanine substitutes glutamine 109 of a FGF-21 variant of SEQ ID NO:7, or SEQ ID NO: 15.
  • the PEG moiety has a molecular weight of about 30 kDa. In some aspects, the PEG moiety has between about 600 and about 800 ethylene glycol units. In some aspects, the PEG moiety is PEGesi.
  • the present disclosure provides methods of treating or preventing NASH in a subject in need thereof, comprising administering to the subject a FGF-21 conjugate of SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, or 16, in combination with a CCR2/5 dual antagonist, e.g., Compound A or Compound C.
  • the subject may exhibit NASH CRN fibrosis stage 1-3, which optionally is determined by a liver biopsy.
  • the subject prior to treatment the subject may exhibit a fatty liver index of at least about 60.
  • prior to treatment the subject may exhibit a hepatic fat fraction percentage of at least 10%, which optionally is determined by magnetic resonance imaging.
  • the disclosure provides a method of treating type 1 diabetes or type 2 diabetes in a subject in need thereof, comprising administering to the subject a FGF-21 polypeptide disclosed herein, e.g., a PEG-FGF-21 of SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, or 16, in combination with a CCR2/5 dual antagonist, e.g., Compound A or Compound C.
  • a FGF-21 polypeptide disclosed herein e.g., a PEG-FGF-21 of SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, or 16
  • a CCR2/5 dual antagonist e.g., Compound A or Compound C.
  • the disclosure provides a method of treating obesity in a subject in need thereof, comprising administering to the subject a FGF-21 polypeptide disclosed herein, e.g., a PEG-FGF-21 of SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, or 16, in combination with a CCR2/5 dual antagonist, e.g., Compound A or Compound C.
  • a FGF-21 polypeptide disclosed herein e.g., a PEG-FGF-21 of SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, or 16
  • a CCR2/5 dual antagonist e.g., Compound A or Compound C.
  • the disclosure provides a method of regulating at least one of glucose and lipid homeostasis, glucose uptake, GLUT 1 expression, and/or serum concentrations of glucose, triglycerides, insulin or glucagon in a subject in need thereof, comprising administering to the subject a FGF-21 polypeptide disclosed herein, e.g., a PEG-FGF-21 of SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, or 16, in combination with a CCR2/5 dual antagonist, e.g., Compound A or Compound C.
  • a FGF-21 polypeptide disclosed herein e.g., a PEG-FGF-21 of SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, or 16
  • a CCR2/5 dual antagonist e.g., Compound A or Compound C.
  • the disclosure provides a method of increasing insulin sensitivity, increasing levels of adiponectin, reducing levels of blood glucose, reducing levels of glucagon, reducing levels of triglyceride, reducing levels of fructosamine, reducing levels of low density cholesterol, or reducing levels of C-reactive protein in a subject in need thereof, comprising administering to the subject a FGF-21 polypeptide disclosed herein, e.g., a PEG-FGF-21 of SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, or 16, in combination with a CCR2/5 dual antagonist, e.g., Compound A or Compound C.
  • a FGF-21 polypeptide e.g., a PEG-FGF-21 of SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, or 16
  • a CCR2/5 dual antagonist e.g., Compound A or Compound C.
  • the disclosure provides a method of treating a condition or disorder selected from obesity, diabetes, pancreatitis, insulin resistance, hyperinsulinemia, glucose intolerance, hyperglycemia, metabolic syndrome, impaired glucose tolerance, inadequate glucose clearance, high blood glucose, and Prader-Willi syndrome in a subject in need thereof, comprising administering to the subject a FGF-21 polypeptide disclosed herein, e.g., a PEG- FGF-21 of SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, or 16, in combination with a CCR2/5 dual antagonist, e.g., Compound A or Compound C.
  • a FGF-21 polypeptide e.g., a PEG- FGF-21 of SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, or 16
  • a CCR2/5 dual antagonist e.g., Compound A or Compound C.
  • the disclosure provides a method of treating an insulin related condition or disorder selected from Type A Insulin Resistance, Type C Insulin Resistance (AKA HAIR- AN Syndrome), Rabson-Mendenhall Syndrome, Donohue's Syndrome or Leprechaunism, hyperandrogenism, hirsuitism, or acanthosis nigricans in a subject in need thereof, comprising administering to the subject a FGF-21 polypeptide disclosed herein, e.g., a PEG-FGF-21 of SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, or 16, in combination with a CCR2/5 dual antagonist, e.g., Compound A or Compound C.
  • a FGF-21 polypeptide e.g., a PEG-FGF-21 of SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, or 16
  • a CCR2/5 dual antagonist e.g., Compound A or Compound C.
  • the present disclosure is directed to a combination therapy of a fibroblast growth factor 21 (FGF-21) polypeptide and a CCR2/5 dual antagonist.
  • FGF-21 polypeptide useful for the present methods can be any variants or fragments of a wild-type FGF-21 polypeptide.
  • the FGF-21 polypeptide is conjugated to a heterologous moiety (e.g., PEG moiety ("FGF-21 conjugate")).
  • FGF-21 conjugate e.g., PEG moiety
  • the FGF-21 polypeptide is linked to a heterologous polypeptide.
  • the FGF-21 polypeptide is linked to a heterologous polypeptide and conjugated to a heterologous moiety.
  • FGF-21 conjugate refers to a conjugate comprising a FGF-21 polypeptide moiety linked to a PEG moiety.
  • the PEG moiety comprises a distal methoxy (-O-CEE) group.
  • FGF-21 polypeptide refers generically to both the wildtype FGF-21 polypeptide (e.g., a polypeptide of SEQ ID NO:3 or 11), to a "variant FGF-21 polypeptide” (e.g., a polypeptide of SEQ ID NO:7 or 15).
  • PEG-FGF-21 conjugate or “PEG-FGF-21” refer to PEGylated FGF-21 forms comprising a PEG moiety linked to a variant FGF-21 polypeptide moiety via an oxime linkage.
  • Exemplary PEG-FGF-21 conjugates of the present disclosure are set forth in SEQ ID NO: 2, 4, 6 and 8 in TABLE 1, below.
  • PEG-FGF-21 conjugates of the present disclosure comprising forms of the polypeptides having the sequences set forth in SEQ ID Nos: 2, 4, 6, and 8, but without an N-terminal methionine correspond to SEQ ID NOS: 10, 12, 14, or 16.
  • FGF-21 variant refers to an FGF-21 polypeptide comprising a Glyl71Glu point mutation and a 120-PGNKSPHRDPAPRG-133 (SEQ ID NO: 17) > GSGRG (SEQ ID NO: 18) substitution with the respect to the sequence of wild type FGF-21.
  • an FGF-21 variant disclosed herein corresponds to FGF-21 sequence set forth in SEQ ID NO: 5 or SEQ ID NO: 7, or their corresponding forms without an N-terminal methionine, i.e., SEQ ID NO: 13 and SEQ ID NO: 15.
  • an FGF-21 variant disclosed herein corresponds to a conjugate set forth in SEQ ID NO: 6 or SEQ ID NO: 8, or their corresponding forms without an N-terminal methionine, i.e., SEQ ID NO: 14 and SEQ ID NO 16:.
  • the compound of SEQ ID NO: 1 or its form without N-terminal methionine of SEQ ID NO: 9 can be replaced with the compound of SEQ ID NO:5 or its form without N-terminal methionine of SEQ ID NO: 13;
  • the compound of SEQ ID NO:2 or its form without N-terminal methionine of SEQ ID NO: 10 can be replaced with the compound of SEQ ID NO: 6 or its form without N-terminal methionine of SEQ ID NO: 14;
  • the compound of SEQ ID NO: 3 or its form without N-terminal methionine of SEQ ID NO: 11 can be replaced with the compound of SEQ ID NO:7 or its form without N-terminal methionine of SEQ ID NO: 15;
  • the compound of SEQ ID NON or its form without N-terminal methionine of SEQ ID NO: 12 can be replaced with the compound of SEQ ID NO:8 or its form without N-terminal methion
  • FGF-21 Fibroblast growth factor 21
  • FGF-21 Fibroblast growth factor 21
  • FGF-21 Multiple polymorphisms of FGF-21 have been identified. Leucine or Proline have been described at the same position in U.S. Patent Publication No. 20010012628 and U.S. Pat. No. 6,716,626. N-terminal leader or signal sequences that differ by 1 amino acid (leucine) are shown in U.S. Pat. No. 6,716,626 and U.S. Patent Publication No. 20040259780. FGF-21 variants or mutants include, but are not limited to, those disclosed in U.S. Pat. No. 6,716,626; U.S. Patent Publication Nos.
  • variant FGF-21 and “variant FGF-21 polypeptide” refer to a FGF-21 polypeptide that differs from a reference wild-type FGF-21 polypeptide (e.g., a wild-type human FGF-21 of SEQ ID NO: 3 or its form without N-terminal methionine of SEQ ID NO: 11) in at least one amino acid position and typically has at least one biological activity of a fibroblast growth factor 21, as well as FGF-21 analogs, FGF-21 isoforms, FGF-21 mimetics, FGF-21 fragments, hybrid FGF-21 proteins, fusion proteins, oligomers and multimers, homologues, glycosylation pattern variants, splice variants, and muteins thereof, regardless of the biological activity of the same.
  • a reference wild-type FGF-21 polypeptide e.g., a wild-type human FGF-21 of SEQ ID NO: 3 or its form without N-terminal methionine of SEQ ID NO: 11
  • FGF-21 analogs FGF
  • the term encompasses both naturally occurring and non-naturally occurring variants, e.g., a variant resulting from the substitution of an amino acid in a wild-type FGF-21 polypeptide, e.g., a polypeptide of SEQ ID NO:3 or its form without N-terminal methionine of SEQ ID NO: 11, with a non-natural amino acid (e.g., para-acetyl-L- phenylalanine).
  • the substitution can be, for example, the result of recombinant expression or chemical or enzymatic synthesis.
  • a variant FGF-21 polypeptide of the present disclosure comprises, consists, or consists essentially of a polypeptide of SEQ ID NO: 1 or its form without N-terminal methionine of SEQ ID NO: 9, or SEQ ID NO: 5 or its form without N- terminal methionine of SEQ ID NO: 13.
  • variant FGF-21 polypeptides of the present disclosure encompass a FGF-21 polypeptide comprising one or more amino acid substitutions, additions or deletions.
  • a variant FGF-21 polypeptide of the present disclosure comprises one or more amino acid substitutions (for example with naturally occurring or non-naturally occurring amino acids), deletions (terminal or internal deletions), or modification such as the attachment of a heterologous moiety (C-terminal, N-terminal, or internal, either by intercalation/insertion in the amino acid sequence or by side-chain attachment).
  • variant FGF-21 polypeptide also encompasses polymorphisms (e.g., naturally occurring FGF-21 sequence variants), e.g., the P- form or L-form of FGF-21.
  • substitutions in a wide variety of amino acid positions in naturally-occurring FGF-21 polypeptide have been described. Substitutions including but not limited to, those that modulate solubility or stability, increase agonist activity, increase in vivo or in vitro half-life, increase protease resistance, convert the polypeptide into an antagonist, reduce immunogenicity or toxicity, facilitate purification or manufacturability, or any combination thereof, and are also encompassed by the term variant FGF-21 polypeptide.
  • variant FGF-21 polypeptide also includes biologically-active fragments, biologically active variants and stereoisomers of the naturally-occurring FGF-21 polypeptide as well as agonist, mimetic, and antagonist variants of the naturally-occurring FGF-21 and polypeptide fusions thereof. Fusions comprising additional amino acids at the amino terminus, carboxyl terminus, or both, are encompassed by the term variant FGF-21 polypeptide.
  • Exemplary fusions include, but are not limited to, e.g., methionyl FGF-21 in which a methionine is linked to the N-terminus of a FGF-21 polypeptide resulting, for example, from the recombinant expression of the mature form of FGF-21 lacking the leader or signal peptide or portion thereof (a methionine is linked to the N-terminus of FGF-21 resulting from the recombinant expression, e.g. in E. coh).
  • fusions for the purpose of purification including, but not limited to, to poly-histidine or affinity epitopes).
  • variant FGF-21 polypeptide also includes glycosylated FGF-21 polypeptides, such as but not limited to, polypeptides glycosylated at any amino acid position, N- linked or O-linked glycosylated forms of the polypeptide. Variants containing single nucleotide changes are also considered as biologically active variants of FGF-21. In addition, splice variants are also included.
  • variant FGF-21 polypeptide also includes FGF-21 heterodimers, homodimers, heteromultimers, or homomultimers of any one or more unmodified or modified F GF -2 Is or any other polypeptide, protein, carbohydrate, polymer, small molecule, linker, ligand, or other biologically active molecule of any type, linked by chemical means or expressed as a fusion protein, as well as polypeptide analogues containing, for example, specific deletions or other modifications yet maintain biological activity.
  • the variant FGF-21 polypeptide comprises an addition, substitution or deletion that increases the affinity of the FGF-21 polypeptide for its receptor.
  • the term variant FGF-21 polypeptide comprises chemically or enzymatically cleavage sequences, protease-cleaved sequences, reactive groups, antibody-binding domains (including but not limited to, FLAG or poly-His) or other affinity based sequences (including, but not limited to, FLAG, poly-His, GST, etc.) or linked molecules (including, but not limited to, biotin) that improve detection (including, but not limited to, GFP), purification, transport through tissues or cell membranes, prodrug release or activation, FGF-21 polypeptide size reduction, or other traits of the polypeptide.
  • the variant FGF-21 polypeptide comprises a polypeptide having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% amino acid sequence identity to the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5 or SEQ ID NO: 7, or their respective forms without N-terminal methionine of SEQ ID NOS: 13 or 15, wherein the polypeptide has a FGF-21 activity.
  • the variant FGF-21 polypeptide consists or consists essentially of a polypeptide having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% amino acid sequence identity to the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5 or SEQ ID NO: 7, or their respective forms without N- terminal methionine of SEQ ID NOS: 9, 11, 13, or 15, wherein the polypeptide has a FGF-21 activity.
  • Variant FGF-21 polypeptides encompassed by this definition include, e.g., variant FGF-21 polypeptides comprising at least one non-natural amino acid.
  • the non- natural amino acid is an amino acid which upon reaction with an aminooxy derivative can form a stable oxime linkage, e.g., p-acetylphenylalanine, m-acetylphenylalanine, p-(3-oxobutenoyl)-L- phenylalanine, p-(2-amino-3 -hydroxy ethyl)phenylalanine, and the like.
  • the nonnatural amino acid is p-acetylphenylalanine.
  • the non-natural amino acid is p- acetyl -L-pheny 1 al anine .
  • one or more non-natural amino acids are incorporated in one or more of the following positions of wild type FGF-21 : before position 1 (i.e. at the N-terminus), 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29,
  • a variant FGF-21 of the present disclosure is a modified FGF-21 polypeptide SEQ ID NO: 1 or SEQ ID NO: 9, i.e., a derivative of the wild type FGF-21 of SEQ ID NO: 3, or its form without N-terminal methionine of SEQ ID NO: 11, in which glutamine 109 of wild type FGF-21 has been substituted with a non-natural para-acetyl-L- phenylalanine amino acid.
  • a variant FGF-21 of the present disclosure is a modified FGF-21 polypeptide SEQ ID NO: 5 or SEQ ID NO: 13 , i.e., a derivative of the FGF- 21 variant of SEQ ID NO: 7, or its form without N-terminal methionine of SEQ ID NO: 15, in which glutamine 109 of the FGF-21 variant has been substituted with a non-natural para-acetyl- L-phenylalanine amino acid.
  • the FGF-21 polypeptide comprises an FGF-21 portion and a non- FGF-21 portion, e.g., a half-life extending moiety.
  • exemplary non-FGF-21 portions include a polypeptide moiety or a non-polypeptide moiety, e.g., Fc, XTEN, albumin, a PAS sequence, transferrin, CTP (28 amino acid C-terminal peptide (CTP) of human chorionic gonadotropin (hCG) with its 4 O-glycans), polyethylene glycol (PEG), hydroxyethyl starch (HES), albumin binding polypeptide, and albumin-binding small molecules.
  • CTP 28 amino acid C-terminal peptide
  • HES hydroxyethyl starch
  • Exemplary FGF-21 polypeptides of the disclosure include, e.g., FGF-21-Fc polypeptides, FGF-21-XTEN polypeptides, FGF-21- albumin polypeptides, FGF-21-PAS polypeptides, FGF-21 -transferrin polypeptides, FGF-21- CTP polypeptides, FGF-21-PEG polypeptides, FGF-21-HES polypeptides, FGF-21 -albumin binding polypeptide polypeptides, and FGF-21 -albumin-binding small molecule polypeptides.
  • an FGF-21 polypeptide can be a fusion protein.
  • exemplary FGF-21 polypeptides include FGF-21 fused to one or more XTEN polypeptides. Schellenburger et al., Nat. Biotech. 27: 1186-90 (2009), which is incorporated herein by reference in its entirety.
  • the XTEN polypeptide can be fused to either the N-terminal end of FGF-21 or to the C-terminal end of FGF-21.
  • Exemplary XTEN polypeptides include, e.g., those disclosed in WO 2009/023270, WO 2010/091122, WO 2007/103515, US 2010/0189682, and US 2009/0092582, each of which is incorporated herein by reference in its entirety.
  • exemplary FGF-21 polypeptides also include FGF-21 fused to one or more albumin polypeptides, albumin binding polypeptides, or albumin-binding small molecules.
  • the albumin is human albumin.
  • the albumin or albumin binding protein can be fused to either the N-terminal end of FGF-21 or to the C-terminal end of FGF-21 or inserted between two amino acids in FGF-21.
  • albumin e.g., fragments thereof, that may be used in the present disclosure are known, e.g., U.S. Patent No. 7,592,010; U.S. Patent No. 6,686,179; and Schulte, Thrombosis Res. 124 Suppl. 2:S6-S8 (2009), each of which is incorporated herein by reference in its entirety.
  • the albumin binding polypeptides can compromise, without limitation, bacterial albumin-binding domains, albumin-binding peptides, or albumin-binding antibody fragments that can bind to albumin.
  • Domain 3 from streptococcal protein G, as disclosed by Kraulis et al., FEBS Lett. 378:190-194 (1996) and Linhult et al., Protein Sci. 11 :206-213 (2002) is an example of a bacterial albumin-binding domain.
  • albumin-binding peptides include a series of peptides having the core sequence DICLPRWGCLW (SEQ ID NO: 19). See, e,g., Dennis et al., J. Biol. Chem.
  • albumin-binding antibody fragments are disclosed in Muller and Kontermann, Curr. Opin. Mol. Ther. 9:319-326 (2007); Rooverset et al., Cancer Immunol. Immunother. 56:303-317 (2007), and Holt et al., Prot. Eng. Design Sci., 21 :283-288 (2008), which are incorporated herein by reference in their entireties.
  • a recombinant FGF-21 polypeptide of the disclosure comprises at least one attachment site for a non-polypeptide small molecule, variant, or derivative that can bind to albumin thereof.
  • albumin binding moieties is 2-(3- maleimidopropanamido)-6-(4-(4-iodophenyl)butanamido)hexanoate (“Albu” tag) as disclosed by Trusselet et al.. Bioconjugate Chem. 20:2286-2292 (2009).
  • exemplary FGF-21 polypeptides also include FGF-21 fused to at least one P subunit of the C-terminal peptide (CTP) of human chorionic gonadotropin or fragment, variant, or derivative thereof.
  • CTP C-terminal peptide
  • the CTP can be fused to FGF-21 either the N-terminal end of FGF-21 or to the C-terminal end of FGF-21 or inserted between two amino acids in FGF- 21.
  • One or more CTP peptides fused to or inserted into a recombinant protein is known to increase the in vivo half-life of that protein. See, e.g., U.S. Patent No. 5,712,122, incorporated by reference herein in its entirety.
  • Exemplary CTP peptides can also be found in U.S. Patent Application Publication No. US 2009/0087411 Al, incorporated by reference.
  • exemplary FGF-21 polypeptides also include FGF-21 fused to at least one PAS sequence or fragment, variant, or derivative thereof.
  • a PAS peptide or PAS sequence as used herein, means an amino acid sequence comprising mainly alanine and serine residues or comprising mainly alanine, serine, and proline residues, the amino acid sequence forming random coil conformation under physiological conditions.
  • the PAS sequence is a building block, an amino acid polymer, or a sequence cassette comprising, consisting essentially of, or consisting of alanine, serine, and proline which can be used as a part of the heterologous moiety in the chimeric protein.
  • amino acid polymer also can form random coil conformation when residues other than alanine, serine, and proline are added as a minor constituent in the PAS sequence.
  • minor constituent is meant that that amino acids other than alanine, serine, and proline can be added in the PAS sequence to a certain degree, e.g, up to about 12%, i.e., about 12 of 100 amino acids of the PAS sequence, up to about 10%, up to about 9%, up to about 8%, about 6%, about 5%, about 4%, about 3%, i.e. about 2%, or about 1%, of the amino acids.
  • the amino acids different from alanine, serine and proline cab be selected from the group consisting of Arg, Asn, Asp, Cys, Gin, Glu, Gly, His, He, Leu, Lys, Met, Phe, Thr, Trp, Tyr, and Vai.
  • a PAS peptide forms a random coil conformation and thereby can mediate an increased in vivo and/or in vitro stability to a recombinant protein of the invention, and has procoagulant activity.
  • PAS sequences are known from, e.g., US Pat. Publ. No. 2010/0292130 Al and PCT Appl. Publ. No. WO 2008/155134 Al. European issued patent EP2173890.
  • exemplary FGF-21 polypeptides also include FGF-21 fused to at least one transferrin peptide or fragment, variant, or derivative thereof. Any transferrin can be fused to or inserted into a recombinant FGF-21 protein of the invention.
  • Tf wildtype human Tf
  • wildtype human Tf is a 679 amino acid protein, of approximately 75 KDa (not accounting for glycosylation), with two main domains, N (about 330 amino acids) and C (about 340 amino acids), which appear to originate from a gene duplication. See GenBank accession numbers NM001063, XM002793, M12530, XM039845, XM 039847 and S95936
  • Transferrin transports iron through transferrin receptor (TfR)-mediated endocytosis. After the iron is released into an endosomal compartment and Tf-TfR complex is recycled to cell surface, the Tf is released back extracellular space for next cycle of iron transporting. Tf possesses a long half-life that is in excess of 14-17 days (Li et al., Trends Pharmacol. Sci. 23:206-209 (2002)). Transferrin fusion proteins have been studied for half-life extension, targeted deliver for cancer therapies, oral delivery and sustained activation of proinsulin (Brandsma et al., Biotechnol. Adv., 29: 230-238 (2011); Bai et al., Proc. Natl. Acad. Sci. USA W2 1291-12% (2005); Kim et al., J. Pharmacol. Exp. Ther., 334:682-692 (2010); Wang et al., J. Controlled Release 155:386-392 (2011)).
  • TfR transferr
  • exemplary FGF-21 polypeptides also include FGF-21 fused to at least one hydroxyethyl starch (HES) polymer.
  • HES hydroxyethyl starch
  • HES is a derivative of naturally occurring amylopectin and is degraded by alpha-amylase in the body. HES exhibits advantageous biological properties and is used as a blood volume replacement agent and in hemodilution therapy in the clinics. See, e.g., Sommermeyer et al., Whypharmazie 8:271-278 (1987); and Weidler et al., Arzneim.-Forschung/Drug Res. 41 : 494-498 (1991).
  • HES is mainly characterized by the molecular weight distribution and the degree of substitution.
  • HES has a mean molecular weight (weight mean) of from 1 to 300 kD, from 2 to 200kD, from 3 to 100 kD, or from 4 to 70kD.
  • Hydroxy ethyl starch can further exhibit a molar degree of substitution of from 0.1 to 3, from 0.1 to 2, from 0.1 to 0.9, or from 0.1 to 0.8, and a ratio between C2:C6 substitution in the range of from 2 to 20 with respect to the hydroxyethyl groups.
  • HES with a mean molecular weight of about 130 kD is VOLUVEN® from Fresenius.
  • VOLUVEN® is an artificial colloid, employed, e.g., for volume replacement used in the therapeutic indication for therapy and prophylaxis of hypovolaemia.
  • HES attachment methods available to those skilled in the art, e.g., the same PEG attachment methods described above.
  • a variant FGF-21 polypeptide of the present disclosure can be linked to a PEG (polyethylene glycol) moiety.
  • Linkage of PEG to a variant FGF-21 polypeptide disclosed herein can result in changes including, but not limited to, increased or modulated serum (in vivo) half-life, or increased or modulated therapeutic half-life relative to the unmodified form, modulated immunogenicity or toxicity, modulated physical association characteristics such as aggregation and multimer formation, altered receptor binding, altered binding to one or more binding partners, and altered receptor dimerization or multimerization.
  • linkage of PEG to a variant FGF-21 disclosed herein improves or alters pharmacokinetic or biophysical properties including but not limited to increasing the rate of absorption, reducing toxicity, improving solubility, reducing protein aggregation, increasing biological activity and/or target selectivity of the PEGylated FGF-21, increasing manufacturability, and/or reducing immunogenicity (see, e.g., U.S. Pat. No.
  • the variant FGF-21 polypeptide e.g., a FGF-21 polypeptide of SEQ ID NO: 1 or SEQ ID NO:5, or their respective forms without N-terminal methionine of SEQ ID NO: 9 or 13
  • wild-type FGF-21 e.g., a FGF- 21 polypeptide of SEQ ID NO:3, or its form without N-terminal methionine of SEQ ID NO: 11
  • at least one linker can be interposed between the variant FGF-21 polypeptide moiety and the PEG moiety.
  • the PEG moiety comprises a distal methoxy (-0- CFE) group.
  • PEG can be linked to one or more of the following amino acid positions of a wild type FGF-21 polypeptide or variant FGF-21 polypeptide: before position 1 (i.e. at the N- terminus), 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100,
  • the PEG is attached to a side chain of a nonnatural amino acid, e.g., a phenylalanine derivative such as para-acetyl-L-phenylalanine, that substitutes a naturally occurring amino acid at any of the positions disclosed above.
  • a nonnatural amino acid e.g., a phenylalanine derivative such as para-acetyl-L-phenylalanine, that substitutes a naturally occurring amino acid at any of the positions disclosed above.
  • PEGs of the present disclosure includes, but are not limited to, polyethylene glycol, polyethylene glycol propionaldehyde, mono Ci-Cio alkoxy or aryloxy derivatives thereof (described in U.S. Pat. No. 5,252,714 which is incorporated by reference herein), monomethoxypolyethylene glycol, discrete PEG, polypropylene oxide/ethylene oxide copolymer, polyalkylene glycol and derivatives thereof, copolymers of polyalkylene glycols and derivatives thereof, or mixtures thereof.
  • the PEG may have a branched structure. Branched PEGs are described, for example, in U.S. Pat. No.
  • the molecular weight of the PEG is about 30 kDa. Other sizes may be used, depending on the desired profile (e.g., the duration of sustained release desired, the effects, if any on biological activity, the ease in handling, the degree or lack of antigenicity and other known effects of the polyethylene glycol to a protein or analog). In some aspects, the molecular weight of the PEG is about 28 kDa, about 29 kDa, about 30 kDa, about 31 kDa, or about 32 kDa.
  • the molecular weight of the PEG is between about 28 kDa and about 29 kDa, between about 29 kDa and about 30 kDa, between about 30 kDa and about 31 kDa, or between about 31 kDa and about 32 kDa.
  • the PEG has about 600 ethylene glycol units, about 610 ethylene glycol units, about 620 ethylene glycol units, about 630 ethylene glycol units, about 640 ethylene glycol units, about 650 ethylene glycol units, about 660 ethylene glycol units, about 670 ethylene glycol units, about 680 ethylene glycol units, about 690 ethylene glycol units, about 700 ethylene glycol units, about 710 ethylene glycol units, about 720 ethylene glycol units, about 730 ethylene glycol units, about 740 ethylene glycol units, about 750 ethylene glycol units, about 760 ethylene glycol units, about 770 ethylene glycol units, about 780 ethylene glycol units, about 790 ethylene glycol units, or about 800 ethylene glycol units.
  • the PEG has between about 600 ethylene glycol units and about 610 ethylene glycol units, between about 610 ethylene glycol units and about 620 ethylene glycol units, between about 620 ethylene glycol units and about 630 ethylene glycol units, between about 630 ethylene glycol units and about 640 ethylene glycol units, between about 640 ethylene glycol units and about 650 ethylene glycol units, between about 650 ethylene glycol units and about 660 ethylene glycol units, between about 660 ethylene glycol units and about 670 ethylene glycol units, between about 670 ethylene glycol units and about 680 ethylene glycol units, between about 680 ethylene glycol units and about 690 ethylene glycol units, between about 690 ethylene glycol units and about 700 ethylene glycol units, between about 700 ethylene glycol units and about 710 ethylene glycol units, between about 710 ethylene glycol units and about 720 ethylene glycol units, between about 720 ethylene glycol units and about 730 ethylene glycol units
  • the PEG has 660, 661, 662, 663, 664, 665, 666, 667, 668, 669, 670, 671, 672, 673, 674, 675, 676, 677, 678, 679, 680, 681, 682, 683, 684, 685, 686, 687, 688, 689, 690, 691, 692, 693, 694, 695, 696, 697, 698, 699, or 700 ethylene glycol units.
  • the PEG moiety is linked to a variant FGF-21 polypeptide of the present disclosure (e.g., a FGF-21 polypeptide of SEQ ID NO: 1 or SEQ ID NO:5, or their respective forms without N-terminal methionine of SEQ ID NO: 9 or SEQ ID NO: 13) via an oxime linkage.
  • a variant FGF-21 polypeptide of the present disclosure e.g., a FGF-21 polypeptide of SEQ ID NO: 1 or SEQ ID NO:5, or their respective forms without N-terminal methionine of SEQ ID NO: 9 or SEQ ID NO: 13
  • the PEG moiety is linked to a variant FGF-21 polypeptide of the present disclosure (e.g., a variant FGF-21 polypeptide of SEQ ID NO: 1 or SEQ ID NO;5, or their respective forms without N-terminal methionine of SEQ ID NO: 9 or SEQ ID NO: 13) via an oxime linkage formed between a reactive group of a PEG molecule (e.g., the aminooxy group of a 30 kDa methyl PEGesi aminooxy molecule) and a reactive group of a non-natural amino acid in the variant FGF-21 polypeptide (e.g., the acetyl group of p-acetyl- phenylalanine, e.g., at amino acid position 109 of the sequence of the variant FGF-21 polypeptide).
  • a reactive group of a PEG molecule e.g., the aminooxy group of a 30 kDa methyl PEGesi aminooxy molecule
  • the non-natural amino acid is para-acetyl-L-phenylalanine replacing Glnl09 of SEQ ID NO: 3 or Glnl09 of SEQ ID NO:7.
  • the PEG moiety is linear and/or comprises a distal methoxy (-O-CEE) group.
  • the FGF-21 conjugate in a formulation disclosed herein is a PEG- FGF-21 of SEQ ID NO: 2, i.e., the FGF-21 of SEQ ID NO: 1 in which glutamine 109 of wild type FGF-21 (SEQ ID NO:3) has been replaced with para-acetyl-L-phenylalanine, and a PEG moiety, e.g., a linear PEG with molecular weight between about 28 kDa and about 32kDa, e.g, about 30 kDa, which has been covalently attached to the para-acetyl-L-phenylalanine via an oxime linkage.
  • the PEG moiety comprises a distal methoxy (-O-CH3) group.
  • the FGF-21 conjugate in a formulation disclosed herein is a PEG- FGF-21 of SEQ ID NO: 10, i.e., the FGF-21 of SEQ ID NO: 9 in which glutamine 109 of wild type FGF-21 (SEQ ID NO: 11) has been replaced with para-acetyl-L-phenylalanine, and a PEG moiety, e.g., a linear PEG with molecular weight between about 28 kDa and about 32kDa, e.g, about 30 kDa, which has been covalently attached to the para-acetyl-L-phenylalanine via an oxime linkage.
  • the PEG moiety comprises a distal methoxy (-O-CH3) group.
  • the FGF-21 conjugate in a formulation disclosed herein is a PEG- FGF-21 of SEQ ID NO: 2, i.e., an FGF-21 conjugate comprising (i) the FGF-21 of SEQ ID NO: 1 in which para-acetyl-L-phenylalanine replaces glutamine 109 of wild type FGF-21 (SEQ ID NO:3), and (ii) a PEG moiety, e.g., a linear PEG with molecular weight between about 28 kDa and about 32kDa, e.g, about 30 kDa, covalently attached to the para-acetyl-L-phenylalanine via an oxime linkage.
  • the PEG moiety comprises a distal methoxy (-O-CH3) group.
  • the FGF-21 conjugate in a formulation disclosed herein is a PEG- FGF-21 of SEQ ID NO: 10, i.e., an FGF-21 conjugate comprising (i) the FGF-21 of SEQ ID NO: 9 in which para-acetyl-L-phenylalanine replaces glutamine 109 of wild type FGF-21 (SEQ ID NO: 11), and (ii) a PEG moiety, e.g., a linear PEG with molecular weight between about 28 kDa and about 32kDa, e.g, about 30 kDa, covalently attached to the para-acetyl-L-phenylalanine via an oxime linkage.
  • the PEG moiety comprises a distal methoxy (-O-CH3) group.
  • the FGF-21 conjugate in a formulation disclosed herein is a PEG- FGF-21 of SEQ ID NO: 4, i.e., the FGF-21 of SEQ ID NO: 1 in which glutamine 109 of wild type FGF-21 (SEQ ID NO:3) has been replaced with para-acetyl-L-phenylalanine, and a linear PEG moiety comprising 681 ethylene glycol units has been covalently attached to the para- acetyl-L-phenylalanine via an oxime linkage.
  • the PEG moiety comprises a distal methoxy (-O-CH3) group.
  • the FGF-21 conjugate in a formulation disclosed herein is a PEG- FGF-21 of SEQ ID NO: 12, i.e., the FGF-21 of SEQ ID NO: 9 in which glutamine 109 of wild type FGF-21 (SEQ ID NO: 11) has been replaced with para-acetyl-L-phenylalanine, and a linear PEG moiety comprising 681 ethylene glycol units has been covalently attached to the para- acetyl-L-phenylalanine via an oxime linkage.
  • the PEG moiety comprises a distal methoxy (-O-CH3) group.
  • the FGF-21 conjugate in a formulation disclosed herein is a PEG- FGF-21 of SEQ ID NO: 4, i.e., an FGF-21 conjugate comprising (i) the FGF-21 of SEQ ID NO: 1 in which para-acetyl-L-phenylalanine replaced glutamine 109 of wild type FGF-21 (SEQ ID NO:3), and (ii) a linear PEG moiety comprising 681 ethylene glycol units covalently attached to the para-acetyl-L-phenylalanine via an oxime linkage.
  • the PEG moiety comprises a distal methoxy (-O-CH3) group.
  • the FGF-21 conjugate in a formulation disclosed herein is a PEG- FGF-21 of SEQ ID NO: 12, i.e., an FGF-21 conjugate comprising (i) the FGF-21 of SEQ ID NO: 9 in which para-acetyl-L-phenylalanine replaced glutamine 109 of wild type FGF-21 (SEQ ID NO: 11), and (ii) a linear PEG moiety comprising 681 ethylene glycol units covalently attached to the para-acetyl-L-phenylalanine via an oxime linkage.
  • the PEG moiety comprises a distal methoxy (-O-CH3) group.
  • the FGF-21 conjugate in a formulation disclosed herein is a PEG- FGF-21 of SEQ ID NO: 6, i.e., the FGF-21 of SEQ ID NO: 5 in which glutamine 109 of the FGF-21 variant of SEQ ID NO: 7 has been replaced with para-acetyl-L-phenylalanine, and a PEG moiety, e.g., a linear PEG with molecular weight between about 28 kDa and about 32kDa, e.g, about 30 kDa, which has been covalently attached to the para-acetyl-L-phenylalanine via an oxime linkage.
  • the PEG moiety comprises a distal methoxy (-O-CH3) group.
  • the FGF-21 conjugate in a formulation disclosed herein is a PEG- FGF-21 of SEQ ID NO: 14, i.e., the FGF-21 of SEQ ID NO: 13 in which glutamine 109 of the FGF-21 variant of SEQ ID NO: 15 has been replaced with para-acetyl-L-phenylalanine, and a PEG moiety, e.g., a linear PEG with molecular weight between about 28 kDa and about 32kDa, e.g, about 30 kDa, which has been covalently attached to the para-acetyl-L-phenylalanine via an oxime linkage.
  • the PEG moiety comprises a distal methoxy (-O-CH3) group.
  • the FGF-21 conjugate in a formulation disclosed herein is a PEG- FGF-21 of SEQ ID NO: 6, i.e., an FGF-21 conjugate comprising (i) the FGF-21 of SEQ ID NO: 5 in which para-acetyl-L-phenylalanine replaces glutamine 109 of FGF-21 variant of SEQ ID NO:7, and (ii) a PEG moiety, e.g., a linear PEG with molecular weight between about 28 kDa and about 32kDa, e.g, about 30 kDa, covalently attached to the para-acetyl-L-phenylalanine via an oxime linkage.
  • the PEG moiety comprises a distal methoxy (-O-CH3) group.
  • the FGF-21 conjugate in a formulation disclosed herein is a PEG- FGF-21 of SEQ ID NO: 14, i.e., an FGF-21 conjugate comprising (i) the FGF-21 of SEQ ID NO: 13 in which para-acetyl-L-phenylalanine replaces glutamine 109 of FGF-21 variant of SEQ ID NO: 15, and (ii) a PEG moiety, e.g., a linear PEG with molecular weight between about 28 kDa and about 32kDa, e.g, about 30 kDa, covalently attached to the para-acetyl-L-phenylalanine via an oxime linkage.
  • the PEG moiety comprises a distal methoxy (-O-CH3) group.
  • the FGF-21 conjugate in a formulation disclosed herein is a PEG- FGF-21 of SEQ ID NO: 8, i.e., the FGF-21 of SEQ ID NO: 5 in which glutamine 109 of the FGF-21 variant of SEQ ID NO:7 has been replaced with para-acetyl-L-phenylalanine, and a linear PEG moiety comprising 681 ethylene glycol units has been covalently attached to the para- acetyl-L-phenylalanine via an oxime linkage.
  • the PEG moiety comprises a distal methoxy (-O-CH3) group.
  • the FGF-21 conjugate in a formulation disclosed herein is a PEG- FGF-21 of SEQ ID NO: 16, i.e., the FGF-21 of SEQ ID NO: 13 in which glutamine 109 of the FGF-21 variant of SEQ ID NO: 15 has been replaced with para-acetyl-L-phenylalanine, and a linear PEG moiety comprising 681 ethylene glycol units has been covalently attached to the para- acetyl-L-phenylalanine via an oxime linkage.
  • the PEG moiety comprises a distal methoxy (-O-CH3) group.
  • the FGF-21 conjugate in a formulation disclosed herein is a PEG- FGF-21 of SEQ ID NO: 8, i.e., an FGF-21 conjugate comprising (i) the FGF-21 of SEQ ID NO: 5 in which para-acetyl-L-phenylalanine replaced glutamine 109 of the FGF-21 variant of SEQ ID NO:7, and (ii) a linear PEG moiety comprising 681 ethylene glycol units covalently attached to the para-acetyl-L-phenylalanine via an oxime linkage.
  • the PEG moiety comprises a distal methoxy (-O-CH3) group.
  • the FGF-21 conjugate in a formulation disclosed herein is a PEG- FGF-21 of SEQ ID NO: 16, i.e., an FGF-21 conjugate comprising (i) the FGF-21 of SEQ ID NO: 13 in which para-acetyl-L-phenylalanine replaced glutamine 109 of the FGF-21 variant of SEQ ID NO: 15, and (ii) a linear PEG moiety comprising 681 ethylene glycol units covalently attached to the para-acetyl-L-phenylalanine via an oxime linkage.
  • the PEG moiety comprises a distal methoxy (-O-CH3) group.
  • the FGF-21 conjugate in a formulation disclosed herein comprises (i) a FGF-21 polypeptide moiety of SEQ ID NO: 1, and (ii) a linear PEG moiety with 681 ethylene glycol units, i.e., a PEG moiety with a molecular weight of approximately 30 kDa, wherein the PEG moiety is covalently attached to the para- acetyl-L-phenylalanine at position 109 via an oxime linkage.
  • the PEG moiety comprises a distal methoxy (-O-CH3) group.
  • the FGF-21 conjugate in a formulation disclosed herein comprises (i) a FGF-21 polypeptide moiety of SEQ ID NO: 9, and (ii) a linear PEG moiety with 681 ethylene glycol units, i.e., a PEG moiety with a molecular weight of approximately 30 kDa, wherein the PEG moiety is covalently attached to the para- acetyl-L-phenylalanine at position 109 via an oxime linkage.
  • the PEG moiety comprises a distal methoxy (-O-CH3) group.
  • the FGF-21 conjugate in a formulation disclosed herein comprises (i) a FGF-21 polypeptide moiety of SEQ ID NO: 5, and (ii) a linear PEG moiety with 681 ethylene glycol units, i.e., a PEG moiety with a molecular weight of approximately 30 kDa, wherein the PEG moiety is covalently attached to the para- acetyl-L-phenylalanine at position 109 via an oxime linkage.
  • the PEG moiety comprises a distal methoxy (-O-CH3) group.
  • the FGF-21 conjugate in a formulation disclosed herein comprises (i) a FGF-21 polypeptide moiety of SEQ ID NO: 13, and (ii) a linear PEG moiety with 681 ethylene glycol units, i.e., a PEG moiety with a molecular weight of approximately 30 kDa, wherein the PEG moiety is covalently attached to the para- acetyl-L-phenylalanine at position 109 via an oxime linkage.
  • the PEG moiety comprises a distal methoxy (-O-CH3) group.
  • the oxime linkage is formed by chemical reaction between a reactive group of a non-natural amino acid present in a variant FGF-21 (e.g., the acetyl group of p-acetyl-phenylalanine) and a reactive group of a PEG molecule (e.g., the aminooxy group of a 30 kDa PEG681 aminooxy molecule comprising a distal methoxy group).
  • a reactive group of a non-natural amino acid present in a variant FGF-21 e.g., the acetyl group of p-acetyl-phenylalanine
  • a PEG molecule e.g., the aminooxy group of a 30 kDa PEG681 aminooxy molecule comprising a distal methoxy group.
  • the non-natural amino acid can be incorporated into the variant FGF-21 polypeptide recombinantly (e.g., by expression in a prokaryotic cell culture), using in vitro transcription and
  • the PEG molecule can be chemically linked to an amino acid (e.g., p-acetyl-phenylalanine), and the PEG- amino acid subsequently incorporated into a FGF-21 polypeptide, for example, via chemical synthesis.
  • the PEG molecule comprises a distal methoxy (-O-CEE) group.
  • FGF-21 polypeptides via yeast expression has been hindered in the past by the presence of O-linked glycosylation, which required site-specific mutagenesis to remove O-linked glycosylation sites.
  • FGF-21 polypeptides also show a substantial degree of glycosylation when produced recombinantly in mammalian cell cultures.
  • the variant FGF-21 polypeptides of the present disclosure are produced recombinantly in prokaryotic cells cultures. Accordingly, in some aspects, the variant FGF-21 polypeptides of the present disclosure are not glycosylated.
  • the present disclosure provided pharmaceutical formulations comprising a FGF-21 conjugate disclosed herein, e.g., a PEG-FGF-21 of SEQ ID NO: 2, 4, 6 or 8, or respective form thereof without N-terminal methionine such as SEQ ID NO: 10, 12, 14, or 16, and an aminopoly carboxylic acid cation chelator, e.g., di ethylenetriaminepentaacetic acid (DTP A).
  • a FGF-21 conjugate e.g., a PEG-FGF-21 of SEQ ID NO: 2, 4, 6 or 8, or respective form thereof without N-terminal methionine such as SEQ ID NO: 10, 12, 14, or 16, and an aminopoly carboxylic acid cation chelator, e.g., di ethylenetriaminepentaacetic acid (DTP A).
  • DTP A di ethylenetriaminepentaacetic acid
  • chelator or “cation chelator” are interchangeable and refer to any substance that is able to remove a metal ion
  • the aminopolycarboxylic acid cation chelator is DTPA.
  • Pentetic acid or diethylenetriaminepentaacetic acid (DTPA) is an aminopolycarboxylic acid consisting of a diethylenetriamine backbone with five carboxymethyl groups.
  • the conjugate base of DTPA has a high affinity for metal cations.
  • the penta-anion DTPA 5- is potentially an octadentate ligand assuming that each nitrogen centre and each COO--group counts as a centre for coordination.
  • the formation constants for its complexes are about 100 greater than those for EDTA.
  • DTPA As a chelating agent, DTPA wraps around a metal ion by forming up to eight bonds. Transition metals, however, usually form less than eight coordination bonds. So, after forming a complex with a metal, DTPA still has the ability to bind to other reagents, as is shown by its derivative pendetide. For example, in its complex with copper(II), DTPA binds in a hexadentate manner utilizing the three amine centres and three of the five carboxylates.
  • the aminopolycarboxylic acid cation chelator can be another aminopolycarboxylic acid cation chelator, such as ethylenediaminetetraacetic acid (EDTA), ethylene glycol-bis(P-aminoethyl ether)-N,N,N',N' -tetraacetic acid (EGTA), 1,4,7,10- tetraazacyclododecane-l,4,7,10-tetraacetic acid (DOTA), or related compound, e.g., tiuxetan (a modified version of DTPA whose carbon backbone contains an isothiocyanatobenzyl and a methyl group).
  • EDTA ethylenediaminetetraacetic acid
  • EGTA ethylene glycol-bis(P-aminoethyl ether)-N,N,N',N' -tetraacetic acid
  • DOTA 1,4,7,10- tetraazacyclodode
  • chelating agents related to DTPA and EDTA known in the art are those in which the nitrogens of the amide groups may be substituted by one or more Ci-is alkyl groups, e.g. DTPA.BMA and EDTA.BMA.
  • the DTPA cation chelator is present in an amount between about 10 pM and about 100 pM, between 15 pM and about 95 pM, between about 20 pM and about 90 pM, between about 25 pM and about 85 pM, between about 30 pM and about 80 pM, between about 35 pM and about 75 pM, between about 40 pM and about 70 pM, between about 45 pM and about 65 pM, between about 50 pM and about 60 pM, between about 25 pM and about 75 pM, between about 40 pM and about 60 pM, between about 30 pM and about 70 pM, or between about 40 pM and about 75 pM.
  • aminopolycarboxylic acid cation chelator e.g., DTPA
  • DTPA aminopolycarboxylic acid cation chelator
  • the pH of the formulation is about 6.8, about 6.9, about 7.0, about 7.1, about 7.2, about 7.3, about 7.4, or about 7.5.
  • the pharmaceutical formulation is more stable than a reference formulation with a pH of 6.5.
  • pharmaceutical formulation further comprises a surfactant.
  • surfactant means any compound, typically an amphipathic molecule, that reduces surface tension when dissolved or suspended in water or water solutions, or which reduces interfacial tension between two liquids, or between a liquid and a solid.
  • a surfactant is any compound that decreases interfacial stress and shear in a solution comprising a FGF-21 conjugate disclosed herein, e.g., a PEG-FGF-21 of SEQ ID NO: 2, 4, 6 or 8, or respective form thereof without N- terminal methionine such as SEQ ID NO: 10, 12, 14, or 16.
  • the surfactant is a nonionic surfactant, i.e., is a surfactant that tends to have no net charge in neutral solutions.
  • the nonanionic surfactant is a polysorbate.
  • Polysorbates are an important class of non-ionic surfactants used widely in protein pharmaceuticals to stabilize the proteins against interface-induced aggregation and to minimize surface adsorption of proteins (Wang W 2005. Protein aggregation and its inhibition in biopharmaceutics. Int J Pharm 289 (1-2): 1-30).
  • Polysorbates are amphiphilic, non-ionic surfactants composed of fatty acid esters of polyoxyethylene (POE) sorbitan.
  • POE polyoxyethylene
  • Commercially available polysorbates are chemically diverse mixtures containing mainly sorbitan POE fatty acid esters.
  • polysorbate refers to oleate esters of sorbitol and its anhydrides, typically copolymerized with ethylene oxide.
  • exemplary polysorbates include Polysorbate 20 (TWEEN 20; PS20) (polyoxyethylene (20) sorbitan monolaurate); Polysorbate 40 (TWEEN 40; PS40) (polyoxyethylene (20) sorbitan monopalmitate); Polysorbate 60 (TWEEN 60; PS60) (polyoxyethylene (20) sorbitan monostearate); and Polysorbate 80 (TWEEN 80; PS80) (polyoxyethylene (20) sorbitan monooleate).
  • the number 20 following the 'polyoxyethylene' part refers to the total number of oxyethylene -(CH2CH2O)- groups found in the molecule.
  • the number following the 'polysorbate' part is related to the type of fatty acid associated with the polyoxyethylene sorbitan part of the molecule. Monolaurate is indicated by 20, monopalmitate is indicated by 40, monostearate by 60, and monooleate by 80.
  • the non-ionic surfactant is present in an amount above the critical micelle concentration (CMC), which for polyoxyethylene sorbitan fatty acid esters is approximately an amount of at least 0.01 mg/ml. See Wan and Lee, Journal of Pharm Sci, 63, p.136, 1974. Surfactant concentrations (%) throughout the present specification correspond to (w/v).
  • the polysorbate is polysorbate 80 (PS80).
  • the pharmaceutical formulation further comprises an amino acid buffering agent.
  • Amino acids may be advantageously used as buffers in pharmaceutical applications because they naturally present substances which are easily metabolizable. Furthermore, amino acids used as buffers can also protect proteins in the amorphous phase if the formulation is freeze-dried.
  • a suitable amino acid buffer can contain histidine, lysine, and/or arginine. Histidine has a good buffering capacity around pH 7.
  • the term "histidine” comprises either L-histidine or D-histidine, a solvated form of histidine, a hydrated form e.g., monohydrate) of histidine, or an anhydrous form of histidine, or a mixture thereof.
  • Other suitable buffers in the formulations of the present disclosure glutamate, Tris, or succinate, to mention just a few.
  • the amino acid buffering agent is L-histidine.
  • the pharmaceutical formulation further comprises an osmotic regulator (also known in the art tonicity agents).
  • an osmotic regulator also known in the art tonicity agents
  • the osmotic regulator can comprises a polyol, a saccharide, a carbohydrate, a salt, such as sodium chloride, or mixtures thereof.
  • Exemplary polyols comprise those with a molecular weight that is less than about 600 kD (e.g., in the range from 120 to 400 kD), e.g., mannitol, trehalose, sorbitol, erythritol, isomalt, lactitol, maltitol, xylitol, glycerol, lactitol, propylene glycol, polyethylene glycol, inositol, or mixtures thereof.
  • 600 kD e.g., in the range from 120 to 400 kD
  • mannitol trehalose
  • sorbitol erythritol
  • isomalt lactitol
  • maltitol maltitol
  • xylitol glycerol
  • lactitol propylene glycol
  • polyethylene glycol inositol, or mixtures thereof.
  • Saccharide or carbohydrate osmotic regulators comprise monosaccharides, disaccharides and polysaccharides or mixtures thereof.
  • the saccharide or carbohydrate is selected from the group consisting of fructose, glucose, mannose, sucrose, sorbose, xylose, lactose, maltose, sucrose, dextran, pullulan, dextrin, cyclodextrins, soluble starch, hydroxyethyl starch, water-soluble glucans, and mixtures thereof.
  • the osmotic regulator comprises a saccharide selected from the group of reducing sugar or non-reducing sugar or mixtures thereof.
  • the osmotic regulator the tonicity agent comprises a saccharide which is a non-reducing sugar, preferably a sugar selected from the group consisting of sucrose, trehalose, and mixtures thereof.
  • the non-reducing sugar is sucrose.
  • a FGF-21 polypeptide disclosed herein e.g., a PEG-FGF-21 of SEQ ID NO: 2, 4, 6 or 8 or respective form thereof without N-terminal methionine such as SEQ ID NO: 10, 12, 14, or 16, is present at a concentration between about 1 mg/ml and about 40 mg/ml.
  • a FGF-21 conjugate disclosed herein e.g., a PEG-FGF-21 of SEQ ID NO: 2, 4, 6 or 8, or respective form thereof without N-terminal methionine such as SEQ ID NO: 10, 12, 14, or 16, is present at a concentration of about 10 mg/ml, about 20 mg/ml, about 30 mg/ml, or about 40 mg/ml.
  • the FGF-21 polypeptide is formulated for subcutaneous administration. In some aspects, the FGF-21 polypeptide is formulated for subcutaneous administration, e.g., with a safety syringe.
  • the present disclosure provides a pharmaceutical formulation comprising (i) a FGF-21 conjugate disclosed herein, e.g., a PEG-FGF-21 of SEQ ID NO: 2, 4, 6 or 8, or respective form thereof without N-terminal methionine such as SEQ ID NO: 10, 12, 14, or 16; (ii) histidine at a concentration between about 10 mM and about 50 mM; (iii) sucrose at a concentration between about 100 mM and about IM; (iv) Polysorbate 80 at a concentration between about 0.01% and about 0.1% (w/v); and, (v) DTPA at a concentration between about 10 pM and about 100 pM; wherein the pH of the formulation is between about 6.7 and about 7.5.
  • a pharmaceutical formulation comprising (i) a FGF-21 conjugate disclosed herein, e.g., a PEG-FGF-21 of SEQ ID NO: 2, 4, 6 or 8, or respective form thereof without N-terminal methionine such as SEQ ID NO: 10, 12, 14, or 16; (ii) histidine at a concentration of about 20 mM; (iii) sucrose at a concentration of about 600 mM; (iv) Polysorbate 80 at a concentration of about 0.05% (w/v); and (v) DTPA at a concentration of about 50 pM; wherein the pH is about 7.1.
  • a FGF-21 conjugate disclosed herein, e.g., a PEG-FGF-21 of SEQ ID NO: 2, 4, 6 or 8, or respective form thereof without N-terminal methionine such as SEQ ID NO: 10, 12, 14, or 16
  • histidine at a concentration of about 20 mM
  • sucrose at a concentration of about 600 mM
  • Polysorbate 80
  • a pharmaceutical formulation comprising (i) a FGF-21 conjugate disclosed herein, e.g., a PEG-FGF-21 of SEQ ID NO: 2, 4, 6 or 8, or respective form thereof without N-terminal methionine such as SEQ ID NO: 10, 12, 14, or 16; (ii) histidine at a concentration of 20 mM; (iii) sucrose at a concentration of 600 mM; (iv) Polysorbate 80 at a concentration of 0.05% (w/v); and (v) DTPA at a concentration of 50 pM; wherein the pH is 7.1.
  • a FGF-21 conjugate disclosed herein, e.g., a PEG-FGF-21 of SEQ ID NO: 2, 4, 6 or 8, or respective form thereof without N-terminal methionine such as SEQ ID NO: 10, 12, 14, or 16
  • histidine at a concentration of 20 mM
  • sucrose at a concentration of 600 mM
  • Polysorbate 80 at a concentration of 0.0
  • a pharmaceutical formulation comprising (i) a FGF-21 conjugate disclosed herein, e.g., a PEG-FGF-21 of SEQ ID NO: 2, 4, 6 or 8, or respective form thereof without N-terminal methionine such as SEQ ID NO: 10, 12, 14, or 16; (ii) histidine at a concentration of about 20 mM; and (iii) sucrose at a concentration of about 600 mM; wherein the pH is about 7.0.
  • a FGF-21 conjugate e.g., a PEG-FGF-21 of SEQ ID NO: 2, 4, 6 or 8, or respective form thereof without N-terminal methionine such as SEQ ID NO: 10, 12, 14, or 16
  • histidine at a concentration of about 20 mM
  • sucrose at a concentration of about 600 mM
  • a pharmaceutical formulation comprising (i) a FGF-21 conjugate disclosed herein, e.g., a PEG-FGF-21 of SEQ ID NO: 2, 4, 6 or 8, or respective form thereof without N-terminal methionine such as SEQ ID NO: 10, 12, 14, or 16; (ii) histidine at a concentration of 20 mM; and (iii) sucrose at a concentration of 600 mM; wherein the pH is 7.0.
  • the present disclosure provide a pharmaceutical formulation comprising (i) a FGF-21 conjugate disclosed herein, e.g., a PEG-FGF-21 of SEQ ID NO: 2, 4, 6 or 8, or respective form thereof without N-terminal methionine such as SEQ ID NO: 10, 12, 14, or 16, at a concentration of about 10 mg/mL; (ii) histidine at a concentration of about 20 mM; (iii) sucrose at a concentration of about 600 mM; (iv) Polysorbate 80 at a concentration of about 0.05% (w/v); and (v) DTPA at a concentration of about 50 uM; wherein the pH is about 7.1.
  • a FGF-21 conjugate disclosed herein e.g., a PEG-FGF-21 of SEQ ID NO: 2, 4, 6 or 8, or respective form thereof without N-terminal methionine such as SEQ ID NO: 10, 12, 14, or 16, at a concentration of about 10 mg/mL
  • histidine at a concentration of
  • a pharmaceutical formulation comprising (i) a FGF-21 conjugate disclosed herein, e.g., a PEG-FGF-21 of SEQ ID NO: 2, 4, 6 or 8, or respective form thereof without N-terminal methionine such as SEQ ID NO: 10, 12, 14, or 16, at a concentration of about 20 mg/mL; (ii) histidine at a concentration of about 20 mM; (iii) sucrose at a concentration of about 600 mM; (iv) Polysorbate 80 at a concentration of about 0.05% (w/v); and (v) DTPA at a concentration of about 50 uM; wherein the pH is about 7.1.
  • a pharmaceutical formulation comprising (i) a FGF-21 conjugate disclosed herein, e.g., a PEG-FGF-21 of SEQ ID NO: 2, 4, 6 or 8, or respective form thereof without N-terminal methionine such as SEQ ID NO: 10, 12, 14, or 16, at a concentration of 10 mg/mL; (ii) histidine at a concentration of 20 mM; (iii) sucrose at a concentration of 600 mM; (iv) Polysorbate 80 at a concentration of 0.05% (w/v); and (v) DTPA at a concentration of 50 uM; wherein the pH is 7.1.
  • a FGF-21 conjugate disclosed herein, e.g., a PEG-FGF-21 of SEQ ID NO: 2, 4, 6 or 8, or respective form thereof without N-terminal methionine such as SEQ ID NO: 10, 12, 14, or 16, at a concentration of 10 mg/mL
  • histidine at a concentration of 20 mM
  • sucrose at
  • a pharmaceutical formulation comprising (i) a FGF-21 conjugate disclosed herein, e.g., a PEG-FGF-21 of SEQ ID NO: 2, 4, 6 or 8, or respective form thereof without N-terminal methionine such as SEQ ID NO: 10, 12, 14, or 16, at a concentration of 20 mg/mL; (ii) histidine at a concentration of 20 mM; (iii) sucrose at a concentration of 600 mM; (iv) Polysorbate 80 at a concentration of 0.05% (w/v); and (v) DTPA at a concentration of 50 uM; wherein the pH is 7.1.
  • a FGF-21 conjugate disclosed herein, e.g., a PEG-FGF-21 of SEQ ID NO: 2, 4, 6 or 8, or respective form thereof without N-terminal methionine such as SEQ ID NO: 10, 12, 14, or 16, at a concentration of 20 mg/mL
  • histidine at a concentration of 20 mM
  • sucrose at
  • the present disclosure provides a pharmaceutical formulation comprising a FGF-21 conjugate of SEQ ID NO:2 at a concentration of 20 g/L in 20 mM histidine, 600 mM sucrose, 50 uM DTPA, and 0.05% PS80, pH 7.1.
  • the present disclosure provides a pharmaceutical formulation comprising a FGF-21 conjugate of SEQ ID NO: 10 at a concentration of 20 g/L in 20 mM histidine, 600 mM sucrose, 50 uM DTPA, and 0.05% PS80, pH 7.1.
  • the present disclosure provides a pharmaceutical formulation comprising a FGF-21 conjugate of SEQ ID NO:4 at a concentration of 10 g/L in 20 mM histidine, 600 mM sucrose, 50 uM DTPA, and 0.05% PS80 (w/v), pH 7.1.
  • the present disclosure provides a pharmaceutical formulation comprising a FGF-21 conjugate of SEQ ID NO: 12 at a concentration of 10 g/L in 20 mM histidine, 600 mM sucrose, 50 uM DTPA, and 0.05% PS80 (w/v), pH 7.1.
  • the present disclosure provides a pharmaceutical formulation comprising a FGF-21 conjugate of SEQ ID NO:4 at a concentration of 20 g/L in 20 mM histidine, 600 mM sucrose, 50 uM DTP A, and 0.05% PS80, pH 7.1.
  • the present disclosure provides a pharmaceutical formulation comprising a FGF-21 conjugate of SEQ ID NO: 12 at a concentration of 20 g/L in 20 mM histidine, 600 mM sucrose, 50 uM DTP A, and 0.05% PS80, pH 7.1.
  • the present disclosure provides a pharmaceutical formulation comprising a FGF-21 conjugate of SEQ ID NO:4 at a concentration of 10 g/L in 20 mM histidine, 600 mM sucrose, 50 uM DTP A, and 0.05% PS80 (w/v), pH 7.1.
  • the present disclosure provides a pharmaceutical formulation comprising a FGF-21 conjugate of SEQ ID NO: 12 at a concentration of 10 g/L in 20 mM histidine, 600 mM sucrose, 50 uM DTP A, and 0.05% PS80 (w/v), pH 7.1.
  • the present disclosure provides a pharmaceutical formulation comprising a FGF-21 conjugate of SEQ ID NO:6 at a concentration of 20 g/L in 20 mM histidine, 600 mM sucrose, 50 uM DTP A, and 0.05% PS80, pH 7.1.
  • the present disclosure provides a pharmaceutical formulation comprising a FGF-21 conjugate of SEQ ID NO: 14 at a concentration of 20 g/L in 20 mM histidine, 600 mM sucrose, 50 uM DTP A, and 0.05% PS80, pH 7.1.
  • the present disclosure provides a pharmaceutical formulation comprising a FGF-21 conjugate of SEQ ID NO:4 at a concentration of 10 g/L in 20 mM histidine, 600 mM sucrose, 50 uM DTP A, and 0.05% PS80 (w/v), pH 7.1.
  • the present disclosure provides a pharmaceutical formulation comprising a FGF-21 conjugate of SEQ ID NO: 12 at a concentration of 10 g/L in 20 mM histidine, 600 mM sucrose, 50 uM DTP A, and 0.05% PS80 (w/v), pH 7.1.
  • the present disclosure provides a pharmaceutical formulation comprising a FGF-21 conjugate of SEQ ID NO:8 at a concentration of 20 g/L in 20 mM histidine, 600 mM sucrose, 50 uM DTP A, and 0.05% PS80, pH 7.1.
  • the present disclosure provides a pharmaceutical formulation comprising a FGF-21 conjugate of SEQ ID NO: 16 at a concentration of 20 g/L in 20 mM histidine, 600 mM sucrose, 50 uM DTP A, and 0.05% PS80, pH 7.1.
  • the present disclosure provides a pharmaceutical formulation comprising a FGF-21 conjugate of SEQ ID NO:4 at a concentration of 10 g/L in 20 mM histidine, 600 mM sucrose, 50 uM DTP A, and 0.05% PS80 (w/v), pH 7.1.
  • the present disclosure provides a pharmaceutical formulation comprising a FGF-21 conjugate of SEQ ID NO: 12 at a concentration of 10 g/L in 20 mM histidine, 600 mM sucrose, 50 uM DTP A, and 0.05% PS80 (w/v), pH 7.1.
  • the formulation is frozen.
  • the formulation is stored in a bag, e.g., a clam shell bag.
  • the bag e.g., a clam shell bag, has a volume between 6L and 12L.
  • the formulation is contained in a vial. In some aspects, the formulation is contained in a syringe. In some aspects, the syringe is a safety syringe. In some aspects, the syringe is a pre-fillable syringe. In some aspects, the syringe is a BD NEOPAKTM pre- fillable syringe. In some aspects, the formulation is contained in a self-injection device.
  • the present methods include a combination therapy of an FGF-21 polypeptide with a CCR2/5 dual antagonist.
  • a CCR2/5 dual antagonist is a polypeptide, e.g., an antibody, e.g., a bispecific antibody.
  • a CCR2/5 dual antagonist is a small molecule.
  • CCR2/5 dual antagonist refers to a small-molecule antagonist that binds potently to CCR2 and CCR5 receptors and exhibits potent dual inhibition of in vitro receptor-mediated functions such as CCR2- and CCR5-mediated functions such as calcium flux and chemotaxis in response to their respective cognate ligands.
  • Compounds having CCR2/5 dual inhibitory activity are reported in, for example, U.S. Pat. Nos. 8,383,812 and 7,163,937, which are incorporated herein by reference in their entireties.
  • the CCR2/5 dual antagonist is an equipotent dual antagonist of CCR2 and CCR5.
  • the CCR2/5 dual antagonist is a compound of formula (X): or a pharmaceutically acceptable salt thereof, wherein:
  • R 1 is hydrogen or Ci-Ce alkyl
  • R 8 and R 9 are independently selected from hydrogen and Ci-Ce alkyl
  • R 10 is Ci-C 6 alkyl
  • Het is an optionally substituted 3- to 14-membered monocyclic or bicyclic heterocyclyl or heteroaryl ring having at least one nitrogen atom; and R a and R b are each hydrogen, or, together form an oxo group; and Z is NH or CH2.
  • CCR2/5 dual antagonists including (S)-l-((l S,2R,4R)-4-(isopropyl(methyl)amino)-2-propylcyclohexyl)-3-((6- (trifluoromethyl)quinazolin-4-yl)amino)pyrrolidin-2-one (hereinafter referred to as Compound A).
  • Compound A The structure of the CCR2/5 dual antagonist Compound (A) is:
  • the CCR2/5 dual antagonist useful for the present method is Compound A.
  • the CCR2/5 dual antagonist useful for the present method is a pharmaceutically acceptable salt of Compound A. It has been previously shown that Compound A potently blocks binding of CCL2, a ligand for CCR2, to mouse CCR2-expressing cells; potently blocks mouse CCL4, a ligand for CCR5, to mouse CCR5-expressing cells; potently inhibits mouse CCL2- and mouse CCL4-induced functions (e.g., calcium flux, integrin CDl lb upregulation); and is pharmacologically related to Compound C. See Table 1 of US Patent Publication 2019/0224205, published July 25, 2019. US Patent Publication 2019/0224205 is incorporated by reference in its entirety.
  • the CCR2/5 dual antagonist useful for the present method is Compound C.
  • the CCR2/5 dual antagonist useful for the present method is a pharmaceutically acceptable salt of Compound C.
  • Compound C also known as BMS-813160, is currently in Phase II clinical trial (NCT04123379) for treating non-small cell lung cancer (NSCLC) or hepatocellular carcinoma (HCC) in combination with nivolumab.
  • the CCR2/5 dual antagonist can be formulated for suitable administration.
  • Chemokine receptor CCR2 C-C chemokine receptor type 2
  • CCR5 C-C chemokine receptor type 5
  • FGF21 Fibroblast growth factor 21
  • NASH non-alcoholic steatohepatitis
  • CDAA-HFD chronic steatohepatitis
  • FGF21 reduced body weight gain, triglycerides, steatosis and NASH activity
  • CCR2/CCR5 antagonism reduced MoMF, inflammatory markers and hepatic fibrosis.
  • Combination treatment reflected aspects of both therapies in short- and long-term, thereby amplifying beneficial effects on all aspects of steatohepatitis and fibrosis.
  • CCR2/CCR5 antagonism and FGF21 agonism improved NAFLD activity score, ALT levels and steatosis already after 2w of treatment, while significant changes on fibrosis required a longer treatment duration.
  • CCR2/5 inhibition blocked the infiltration of inflammatory monocytes and FGF21 agonism improved obesity-related metabolic disorders.
  • combined therapy ameliorates progressive steatohepatitis and fibrosis synergistically, resulting in a therapeutic action more potent than single drug treatment, therefore confirming the therapeutic effect of combining these two approaches in patients with NASH.
  • NAFL non-alcoholic fatty liver
  • Fibrosis was evaluated using the NASH Clinical Research Network fibrosis staging system (Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41(6): 1313-21).
  • C57BL6/J wildtype (WT) mice were housed in a specific-pathogen-free environment at the Animal Facility of the University Hospital Aachen in a 12-hour light / dark cycle with free access to food and water.
  • In vivo animal experiments were performed with male mice at eight weeks of age under conditions approved by the appropriate institutional and governmental authorities according to German legal requirements (State Agency for Nature, Environment and Consumer Protection in North-Rhine Westphalia, LANUV NRW).
  • Both pharmacologic compounds were provided by Bristol-Myers-Squibb.
  • the CCR2/5 antagonist (Compound A) was dissolved in sterile water at pH 3 containing 0.5% methylcellulose (400cps) and 0.1% Tween-80.
  • the CCR2/5 antagonist was administered via oral gavage (PO) at either 45 mg/kg body weight (BW) b.i.d. in single drug treatment or 15 mg/kg BW b.i.d. in combination treatment.
  • PEG-FGF21 variant FGF21v, also PEG-FGF21v herein
  • PEG-FGF-21 conjugate of SEQ ID NO: 6 having a 30kD PEG moiety was suspended in a vehicle containing 20 mM Tris(hydroxymethyl)aminomethane and 250 mM sucrose at pH 8.3.
  • PEG-FGF21v was administered by subcutaneous (SC) injection at 0.6 mg/kg BW twice weekly.
  • mice were fed a choline-deficient, L-amino acid-defined, high-fat diet enriched with 2% cholesterol (CDAHFD) (El 5673-940, Ssniff, Soest, Germany) for up to 12 weeks.
  • CDAHFD choline-deficient, L-amino acid-defined, high-fat diet enriched with 2% cholesterol
  • Pharmacologic treatment started as single drug or combination therapy after 6 weeks of diet administration. Mice were sacrificed after two or six weeks of treatment for final analysis.
  • Liver and blood leukocytes were analyzed by multicolor flow cytometry using an LSR-Fortessa (BD Biosciences), as described (Mossanen JC, Krenkel O, Ergen C, Govaere O, Liepelt A, Puengel T, et al. Chemokine (C-C motif) receptor 2-positive monocytes aggravate the early phase of acetaminophen-induced acute liver injury. Hepatology. 2016;64(5): 1667-82).
  • Serum CCL2 and FGF21 concentrations in human serum were determined using specific kits (DCP00 and DF2100 respectively, R&D, Oxon, UK) according to the manufacturer’s protocols.
  • Human cytokeratin-18 M30 fragments were measured using the M30 apoptosense ELISA kit (TECOmedical, Nijkerk, The Netherlands).
  • CCL2 or monocyte chemoattractant protein- 1 (MCP-1) is expressed and secreted by various hepatic cells during fibrosis progression, as has been shown in mouse models as well as human patients (Weismün R, Tacke F. Liver Fibrosis: From Pathogenesis to Novel Therapies. Dig Dis. 2016;34(4):410-22; Haukeland JW, Damas JK, Konopski Z, Loberg EM, Haaland T, Goverud I, et al.
  • FGF21 Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2. J Hepatol. 2006;44(6): 1167-74). FGF21 is synthesized and secreted from the liver, and it has multiple metabolic effects (Kharitonenkov A, Shiyanova TL, Koester A, Ford AM, Micanovic R, Galbreath EJ, et al. FGF-21 as a novel metabolic regulator. J Clin Invest. 2005;115(6): 1627-35). Deficient or aberrant FGF21 is associated with NAFLD/NASH, and elevated FGF21 serum levels correlate with hepatic fat content in mice and humans (reviewed in Tucker B, Li H, Long X, Rye KA, Ong KL.
  • Fibroblast growth factor 21 in non-alcoholic fatty liver disease Metabolism. 2019; 101 : 153994].
  • Stage 1 (perisinusoidal or periportal) 15 (48.4)
  • Triglycerides mg/dl 170 (124-199) 185 (142-257) 0.151
  • FGF-21 pg/ml 265.6 (156.4-573.1) 296.4 (189.8-587.3) 0.586
  • Results were expressed as mean ⁇ SD or median (interquartile range) for continuous variables, depending on the normality of the distribution, and n (%) for categorical variables. * P ⁇ 0.05; ** P ⁇ 0.01.
  • ALT Alanine Aminotransferase
  • AST Aspartate Aminotransferase
  • BMI body mass index
  • CCL2 chemokine (C-C motif) ligand 2
  • CK-18 M30 cytokeratin-18 M30 fragments
  • FGF-2 fibroblast growth factor 21
  • GGT y- glutamy Itransferase .
  • Fibrosis was absent, mild or moderate (F0-F2) in 73 patients, while 12 patients had progressed to advanced levels of fibrosis (F3-F4).
  • CCL2 serum levels were significantly elevated in patients with advanced fibrosis compared to those without (P ⁇ 0.001), and also correlated with the FIB-4 score (FIGS. 1A, 1C; TABLE 4).
  • FGF-21 pg/ml 260 (157-537) 674 (281-868) 0.07
  • Results were expressed as mean ⁇ SD or median (interquartile range) for continuous variables, depending on the normality of the distribution, and n (%) for categorical variables. * P ⁇ 0.05; ** P ⁇ 0.01; *** P ⁇ 0.001.
  • ALT Alanine Aminotransferase
  • AST Aspartate Aminotransferase
  • CCL2 chemokine (C-C motif) ligand 2
  • FGF-2 fibroblast growth factor 21
  • GGT y-glutamyltransferase.
  • ALT alanine aminotransferase
  • AST aspartate aminotransferase
  • CCL2 chemokine (C-C motif) ligand 2.
  • CCL2 attracts monocytes via CCR2 to the site of injury leading to the differentiation of monocytes into MoMF, which drive hepatic inflammation and activate hepatic stellate cells (HSC), thereby aggravating fibrosis progression (Weismün R, Tacke F. Liver Fibrosis: From Pathogenesis to Novel Therapies. Dig Dis. 2016;34(4):410-22; Baeck C, Wei X, Bartneck M, Fech V, Heymann F, Gassier N, et al.
  • chemokine C-C motif chemokine ligand 2 (monocyte chemoattractant protein 1) accelerates liver fibrosis regression by suppressing Ly-6C(+) macrophage infiltration in mice. Hepatology. 2014;59(3): 1060-72).
  • CCR2/5 inhibitor CCR2/5i
  • FGF21v PEG- FGF21 variant
  • CCR2/5 inhibition was associated with significantly reduced numbers of hepatic monocytes and F4/80-positive hepatic monocyte- derived macrophages (MoMF) (FIGS. 2B, 2C, and 2G) as well as blood monocytes (FIG. 2F).
  • the reduction in monocytes and MoMF was accompanied by a significant amelioration of the liver injury, as assessed by quantification of the necrotic area fraction (FIGS. 2B and 2C) and serum ALT and AST levels (FIG. 2D).
  • CCR2/5 inhibition did not affect other myeloid or lymphoid immune cell populations (data not shown).
  • CCR2/5 antagonists Puengel T, Krenkel O, Kohlhepp M, Lefebvre E, Luedde T, Trautwein C, et al.
  • CCR2/5 antagonists Puengel T, Krenkel O, Kohlhepp M, Lefebvre E, Luedde T, Trautwein C, et al.
  • FGF21 fibroblast growth factor 21
  • Fibroblast growth factor 21 corrects obesity in mice. Endocrinology. 2008;149(12):6018-27).
  • the CDAHFD liver injury model was used to induce steatohepatitis and liver fibrosis over a total period of 12 weeks, and started pharmacologic treatment from half of the time over the last 6 weeks (FIG. 3A).
  • Counter-regulatory elevated levels of CCL2 and CCL5 in the serum confirmed efficient pharmacologic inhibition of CCR2 and CCR5 (FIG. 5E).
  • Control animals showed a continuous weight gain over time, while CDAHFD fed mice rather maintained their bodyweight. Mice which received PEG-FGF21v demonstrated moderate weight loss compared to CCR2/5 inhibitor-treated mice.
  • liver injury was ameliorated most significantly when PEG-FGF21v was combined with the CCR2/5 antagonist (FIG. 4C).
  • liver triglycerides were moderately (non-significant) reduced with PEG-FGF21v, but significantly lowered in the combination treatment (FIG. 4C).
  • Single drug treatment caused trends (non-significant) towards reduced levels of fibrosis at this timepoint (FIG. 4D), but a stronger fibrosis reduction upon combined therapy with CCR2/5 antagonist and PEG-FGF21v.
  • combination treatment was most effective for all aspects of NAS (FIG. 4C, and data not shown).
  • Cenicriviroc Treatment for Adults with Nonalcoholic Steatohepatitis and Fibrosis Final Analysis of the Phase 2b CENTAUR Study. Hepatology. 2020; Sanyal A, Charles ED, Neuschwander-Tetri BA, Loomba R, Harrison SA, Abdelmalek MF, et al. Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial. Lancet. 2019;392(10165):2705-17).
  • the involvement of many pathophysiological mechanisms and the crosstalk between them in NAFLD could partly explain why targeting a single pathway might be insufficient. Combination treatment is therefore an attractive possibility to overcome these problems, although there is currently little evidence to suggest specific combinations.
  • FGF21 analogue pegbelfermin The efficacy and safety of the FGF21 analogue pegbelfermin is currently being evaluated in a phase 2b clinical study in patients with NASH and stage 3 fibrosis (FALCON1, ClinicalTrials.gov Identifier NCT03486899) and patients with NASH cirrhosis (FALCON2, ClinicalTrials.gov Identifier NCT03486912).
  • Subjects with NAFLD or NASH are treated with an CCR2/5 antagonist (e.g., Compound C, or a pharmaceutically acceptable salt thereof) and a PEG-FGF-21 conjugate (e.g., SEQ ID NO :2 or SEQ ID NO: 4) for 6 months.
  • the subjects are assessed before the study, and at intervals during the study during the therapy and after the last doses of therapy, for safety and pharmacodynamic evaluations.
  • MRIs of the subjects' livers are taken during the therapy and after completion of the therapy, to determine the efficacy, e.g., reduction of hepatic fat.
EP21773170.2A 2020-08-07 2021-08-06 Fgf21 combined with ccr2/5 antagonists for the treatment of fibrosis Withdrawn EP4192495A1 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202063063189P 2020-08-07 2020-08-07
US202063065414P 2020-08-13 2020-08-13
US202063065749P 2020-08-14 2020-08-14
US202063065935P 2020-08-14 2020-08-14
US202063067184P 2020-08-18 2020-08-18
PCT/US2021/045090 WO2022032187A1 (en) 2020-08-07 2021-08-06 Fgf21 combined with ccr2/5 antagonists for the treatment of fibrosis

Publications (1)

Publication Number Publication Date
EP4192495A1 true EP4192495A1 (en) 2023-06-14

Family

ID=77821982

Family Applications (1)

Application Number Title Priority Date Filing Date
EP21773170.2A Withdrawn EP4192495A1 (en) 2020-08-07 2021-08-06 Fgf21 combined with ccr2/5 antagonists for the treatment of fibrosis

Country Status (3)

Country Link
EP (1) EP4192495A1 (ja)
JP (1) JP2023538533A (ja)
WO (1) WO2022032187A1 (ja)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022115597A1 (en) * 2020-11-25 2022-06-02 Bristol-Myers Squibb Company Methods of treating liver diseases

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
AU648020B2 (en) 1989-02-21 1994-04-14 Washington University Modified forms of reproductive hormones
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US7459540B1 (en) 1999-09-07 2008-12-02 Amgen Inc. Fibroblast growth factor-like polypeptides
WO2001032678A1 (en) 1999-11-05 2001-05-10 Smithkline Beecham Corporation sbgFGF-19a
US6716626B1 (en) 1999-11-18 2004-04-06 Chiron Corporation Human FGF-21 nucleic acids
PT1232264E (pt) 1999-11-18 2009-11-26 Novartis Vaccines & Diagnostic Gene fgf-21 humano e produtos da expressão do gene
US20040259780A1 (en) 2001-07-30 2004-12-23 Glasebrook Andrew Lawrence Method for treating diabetes and obesity
CA2471363C (en) 2001-12-21 2014-02-11 Human Genome Sciences, Inc. Albumin fusion proteins
AU2003201810A1 (en) 2002-01-15 2003-07-30 Eli Lilly And Company Method for reducing morbidity and mortality in critically ill patients
ES2298785T3 (es) 2003-06-12 2008-05-16 Eli Lilly And Company Proteinas de fusion.
US7163937B2 (en) 2003-08-21 2007-01-16 Bristol-Myers Squibb Company Cyclic derivatives as modulators of chemokine receptor activity
KR20060135648A (ko) 2003-12-10 2006-12-29 일라이 릴리 앤드 캄파니 섬유모세포 성장인자 21의 뮤테인
WO2005072769A1 (en) 2004-01-26 2005-08-11 Eli Lilly And Company Use of fgf-21 and thiazolidinedione for treating type 2 diabetes
CA2557782A1 (en) 2004-03-17 2005-10-06 Eli Lilly And Company Glycol linked fgf-21 compounds
SI1751184T1 (sl) 2004-05-13 2010-01-29 Lilly Co Eli Fgf-21 fuzijski proteini
DE602005016946D1 (de) 2004-09-02 2009-11-12 Lilly Co Eli Muteine des fibroblasten-wachstumsfaktors 21
EP1789443A1 (en) 2004-09-02 2007-05-30 Eli Lilly And Company Muteins of fibroblast growth factor 21
WO2006050247A2 (en) 2004-10-29 2006-05-11 Neose Technologies, Inc. Remodeling and glycopegylation of fibroblast growth factor (fgf)
WO2006065582A2 (en) 2004-12-14 2006-06-22 Eli Lilly And Company Muteins of fibroblast growth factor 21
US20080261875A1 (en) 2005-01-21 2008-10-23 Eli Lilly And Company Method For Treating Cardiovascular Disease
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
US8048848B2 (en) 2006-02-03 2011-11-01 Prolor Biotech Ltd. Long-acting interferons and derivatives thereof and methods thereof
SI2402754T2 (sl) 2006-03-06 2023-09-29 Amunix Operating Inc. Nestrukturirani rekombinantni polimeri in njihove uporabe
KR101476472B1 (ko) 2007-03-30 2015-01-05 암브룩스, 인코포레이티드 변형된 ｆｇｆ-21 폴리펩티드 및 그 용도
CN101970678B (zh) 2007-06-21 2014-08-20 慕尼黑科技大学 具有增加的体内和/或体外稳定性的生物学活性蛋白
CA2695374A1 (en) 2007-08-15 2009-02-19 Amunix, Inc. Compositions and methods for modifying properties of biologically active polypeptides
JOP20190083A1 (ar) 2008-06-04 2017-06-16 Amgen Inc بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
US9279013B2 (en) 2008-10-10 2016-03-08 Amgen Inc. FGF-21 mutants comprising polyethylene glycol and uses thereof
CN102348715B (zh) 2009-02-03 2017-12-08 阿穆尼克斯运营公司 延伸重组多肽和包含该延伸重组多肽的组合物
US8383812B2 (en) 2009-10-13 2013-02-26 Bristol-Myers Squibb Company N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-3-(7-tert-butylpyrazolo[1,5-A][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide, a dual modulator of chemokine receptor activity, crystalline forms and processes
JP2013533227A (ja) 2010-06-08 2013-08-22 ノヴォ ノルディスク アー／エス Ｆｇｆ２１類似体および誘導体
US9023791B2 (en) 2010-11-19 2015-05-05 Novartis Ag Fibroblast growth factor 21 mutations
AR087973A1 (es) 2011-10-04 2014-04-30 Lilly Co Eli Variantes del factor 21 del crecimiento de fibroblastos
TWI513705B (zh) 2012-06-11 2015-12-21 Lilly Co Eli 纖維母細胞生長因子２１蛋白質
US9434788B2 (en) 2012-07-11 2016-09-06 The United States Of America, As Represented By The Secretary Of Agriculture Bio-based fiber gums (BFGs) and processes for producing BFGs
WO2014144878A2 (en) * 2013-03-15 2014-09-18 The Scripps Research Institute Novel thiol & amino modifying reagents for protein chemistry and methods of use thereof
WO2015143367A2 (en) * 2014-03-21 2015-09-24 Tobira Therapeutics, Inc. Cenicriviroc for the treatment of fibrosis
KR102637699B1 (ko) 2014-10-24 2024-02-19 브리스톨-마이어스 스큅 컴퍼니 변형된 fgf-21 폴리펩티드 및 그의 용도
MA47166A (fr) * 2016-12-28 2021-05-19 Modunex Bio Corp Polythérapie pour la stéatohépatite non alcoolique (shna) et la fibrose hépatique
AU2019209435A1 (en) 2018-01-22 2020-09-17 Bristol-Myers Squibb Company Compositions and methods of treating cancer
BR112022013172A2 (pt) * 2020-01-08 2022-09-13 Bristol Myers Squibb Co Formulações de conjugados de fgf-21

Also Published As

Publication number Publication date
JP2023538533A (ja) 2023-09-08
WO2022032187A1 (en) 2022-02-10

Similar Documents

Publication Publication Date Title
US11382956B2 (en) Amylin analogues
US10766939B2 (en) Amylin analogues
WO2011161226A2 (en) Novel antibody formulation
US20230346957A1 (en) Fgf-21 conjugate formulations
EP4192495A1 (en) Fgf21 combined with ccr2/5 antagonists for the treatment of fibrosis
KR20230121822A (ko) Glp-1/glp-2 이중 효능제의 약학적 조성물
US20240123031A1 (en) Methods of treating liver diseases
KR20230121824A (ko) Glp-1/glp-2 이중 효능제의 약학적 조성물
KR20230121823A (ko) Glp-1/glp-2 이중 효능제의 약학적 조성물
US20210260161A1 (en) Fgf-21 formulations
AU2017274094B2 (en) Compositions and methods for treating metabolic diseases
US20220372111A1 (en) Polypeptide inhibitors of neutrophil elastase activity and uses thereof
WO2022106976A1 (en) Stable pharmaceutical formulations of soluble fgfr3 decoys
US20210283053A1 (en) Liquid formulations of glucagon analogues
CN115884783A (zh) Ghrh类似物的低剂量药物组合物及其用途

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20230302

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20230926